

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **PEYVANDI FLORA**
Address **VIA ANFOSSI, 6, 20135 MILAN, ITALY**
Telephone **+39-02-54125705/55035414**
Fax **+39-02-54100125**
E-mail **flora.peyvandi@unimi.it**
Nationality **Italian**
Date of birth **29/11/1964**

WORK EXPERIENCE

CLINICAL CARE

- 2013 - present IRCCS Maggiore Hospital, University of Milan, Milan – Italy
- Director of the Unit of non tumoral haematology and coagulopathies (U.O.C di Ematologia Non Tumorale e Coagulopatie).
 - Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
- 2010-2013 IRCCS Maggiore Hospital, University of Milan, Milan – Italy
- Director of Department for diagnosis and treatment of coagulopathy
 - Responsible of the Internal Medicine department (OU Internal Medicine 2 and UO Internal Medicine 3).
 - Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
- 2001-2010 IRCCS Maggiore Hospital, University of Milan, Milan - Italy
- Associate medical director
 - Out-patient clinic for the diagnosis and treatment of rare bleeding disorders.
 - Genetic counselling for coagulation disorders
 - Out-patient clinic for the assistance to pregnancy for women affected with rare coagulation disorders and von Willebrand disease; reproductive assistance to HIV discordant couples affected with haemophilia
 - Out-patient clinic for the diagnosis and treatment of thrombotic microangiopathies
- 1996-2001 Royal Free Hospital, London – UK
- 1991-1996 VA Administration Hospital, Harvard Unibversity, Boston, MA - USA
- 1991-1996 IRCCS Maggiore Hospital, University of Milan, Milan – Italy
- Clinical activity in the Department of Internal Medicine and Haematology out-patient clinic

**WORK EXPERIENCE
TEACHING**

- Nov 2012 – present Coordinator of Master of Arts course in Clinical Research, University of Milan, Milan – Italy
- Aug 2011 - Jul 2016 University College of London, Cancer Institute, London – UK
- Visiting Professor working on a project entitled “Identification of genetic risk factors

in autoimmune thrombotic thrombocytopenic purpura” in collaboration with Prof. Samuel Machin (University College of London, London - UK) and Prof. Edward Tuddenham (Royal Free Hospital, London – UK)

- Maj 2009 – Maj 2011 University College of London, Cancer Institute (UCL), London – UK
- Professorial Research Associate
- 2005-present University of Milan, Milan – Italy:
- Associate Professor of Internal Medicine
- Courses on i) Medical Clinic, ii) Medical Therapy, and iii) Internal Medicine at Post-graduate School in Internal Medicine, IRCCS Maggiore Hospital
- Courses on i) Molecular Biology applied to Hematology, ii) Methods and Notions in Haemostasis, iii) Methods and Notions in Immunology, iv) Clinic and Therapy of hemostasis disorders, and v) Internal Medicine at Post-graduate School of Hematology, IRCCS Maggiore Hospital
- Courses on i) Medical Clinic, ii) Medical Therapy, at School of Medicine, IRCCS Maggiore Hospital
- Courses on i) Biotechnological diagnostics, and ii) Cellular and Molecular Therapy at First degree course in Medical Biotechnologies and Molecular Medicine
- Member of the teaching staff and of the managing council of the Post-graduate school in Clinical and Laboratory Biomedical Sciences
- Jan 2005 – Dec 2007 Shiraz University of Medical Sciences, Nemazee Hospital, Shiraz - Iran
- Visiting Professor delivering courses on Molecular medicine, Congenital coagulopathies and thrombosis
- Other courses and activities
- 2001-present Educational courses of World Federation of Hemophilia (WFH)
- 2008-present Educational courses of International Society of Thrombosis and Haemostasis (ISTH)
- 2001-present Co-promoter, PhD degree, Leiden University, Leiden - The Netherlands:
- Luca Andrea Lotta, thesis entitled “Pathophysiology of Thrombotic Thrombocytopenic Purpura: the <Two-Hit> Paradigm”, year: 2012
- Khaled Mousa Saleh Musallam and Ali Taher Taher, thesis entitled “Beta-thalassemia intermedia. Morbidity uncovered”, year: 2012
- Co-Promoter, PhD degree, University of Maastricht, Maastricht - The Netherlands:
- Abdolreza Afrasiabi, thesis entitled “Molecular genetic analysis of patients with Rare Bleeding Disorders in South Iran”, year: 2009
- Tutor of PhD and Master of Arts students, University of Milan, Milan – Italy:
- Ilaria Mancini, thesis entitled “ADAMTS13-related assays in acquired thrombotic thrombocytopenic purpura”, doctorate in Experimental Hematology, year 2011/2012
- Maria Paola Marconi, thesis entitled “Scheda studio: strumento di monitoraggio della conduzione di studi clinici”, Master in Clinical Research, year: 2012/2013
- Giacomo Tuana Franguel, thesis entitled “Demographics, clinical characteristics and genetic determinants of platelet secretion defects”, Master in Clinical Research, year: 2011/2012
- Matteo Rossi, thesis entitled “Factor XIII deficiency, data collection and clinical trial design”, Master in Clinical Research, year: 2010/2011
- Luca Andrea Lotta, thesis entitled “Studies on the genetic predisposition to common thrombotic diseases”, doctorate in Clinical Methodology, year 2010/2011
- Lucia Calò, thesis entitled “Analisi dei problemi ginecologici ed ostetrici nelle donne con coagulopatia a diatesi emorragica attraverso il registro internazionale WRBDD (women with rare bleeding disorders)”, doctorate in Clinical Methodology, year: 2010/2011
- Marzia Menegatti, thesis entitled “The role of factor X in blood coagulation: clinical, phenotypic and molecular analysis of a severe rare bleeding disorder”, doctorate in Experimental Hematology, year 2008/2009
- Margherita Punzo, thesis entitled “Ruolo delle interazioni tra il fattore di von

Willebrand e la Glicoproteina Ib nella megacariocitopoiesi. Studio su piastrine e megacariociti di pazienti affetti da malattia di von Willebrand di tipo 2B", doctorate in Experimental Hematology, year 2008/2009

Supervisor of Graduation thesis, University of Milan, Milan – Italy:

- Sabrina Seregini, thesis entitled "Ricerca di un possibile "founder effect" associato alla mutazione p.Arg1997Trp nel gene del FVIII in un gruppo di pazienti italiani affetti da emofilia A", Degree course in Medical Biotechnologies and Molecular Medicine, year: 2011/2012
- Francesca Ambrosini, thesis entitled "Analisi della discrepanza dei metodi per il dosaggio di ADAMTS13 in pazienti affetti da TTP acquisita: ruolo degli autoanticorpi anti-ADAMTS13", Degree course in Medical Biotechnologies and Molecular Medicine, year: 2010/2011
- Susanna Zanutto, thesis entitled "Caratterizzazione molecolare di pazienti affetti da carenza congenita del Fattore X della coagulazione", Degree course in Medical Biotechnologies, year: 2004/2005

Assistant supervisor of Graduation thesis, University of Milan, Milan – Italy:

- Dino Francesco Augusto Motti, thesis entitled "Pregnancy as a risk factor for thrombotic thrombocytopenic purpura", Degree course in Medicine, year: 2009/2010
- Luca Andrea Lotta, thesis entitled "Caratterizzazione molecolare di un caso di porpora trombotica trombocitopenica congenita", Degree course in Medicine, year: 2007/2008
- Daniele Caldara, thesis entitled "Diagnosi molecolare di emofilia A", Degree course in Medical Biotechnologies, year: 2002/2003
- Roberta Palla, thesis entitled "Analisi molecolare e cellulare di una mutazione naturale (Arg277Cys) a carico del gene del fattore VII della coagulazione in un paziente con carenza grave e sintomi emorragici", Degree course in Medical Biotechnologies, year: 2001/2002

Assistant supervisor of Graduation thesis, University of Piemonte Orientale "Amadeo Avogadro", Vercelli – Italy:

Ermonela Bregu, thesis entitled "Caratterizzazione fenotipica e genetica di pazienti affetti da carenza congenita del Fattore X della coagulazione", Degree course in Medical and Pharmaceutical Biotechnologies, year: 2010/2011

Assistant supervisor of Specialization Degree, School of Medicine, University of Milan, Milan – Italy:

- Raffaella Rossio, thesis entitled "Caratterizzazione biochimica e molecolare dei pazienti affetti da porpora trombotica trombocitopenica e livelli di ADAMTS13 normale", Specialization in Internal Medicine, year: 2011/2012
- Barbara Ferrari, thesis entitled "Porpora Trombotica Trombocitopenica: gravidanza come fattore di rischio", Specialization in Internal Medicine, year: 2011/2012
- Giuseppe Bettoni, thesis entitled "Ruolo degli anticorpi anti ADAMTS13 nella Porpora Trombotica Trombocitopenica", Specialization in Internal Medicine, year: 2009/2010
- Simona Maria Siboni, thesis entitled "Valutazione del ruolo della metalloproteasi ADAMTS13 e degli anticorpi anti-ADAMTS13 in 100 pazienti affetti da porpora trombotica trombocitopenica", Specialization in Hematology, year: 2003/2004

EDUCATION AND TRAINING

Dec 2013-Dec 2017	Award of the National Scientific Qualification ("abilitazione scientifica nazionale") as Full Professor by The Italian Ministry of Education, universities and research (MIUR) (Decreto Direttoriale n. 222/2012)
Oct 2012-present	General Medical Council, London, UK N° 6095693 - Registration as haematologist specialist in UK without licence to practise
Feb 2005-Sept 2012	General Medical Council, London, UK N° 6095693 - Full registration as haematologist specialist in NHS, UK
Jan 2001	Research Doctorate, University of Milan, Milan – Italy

- Nov 2000 - Phenotype and genotype characterization of rare bleeding disorders
PhD, University of Maastricht, Maastricht - The Netherlands
- Jul1998-Jun 1999 - Rare bleeding disorders
Research fellow, Beth Israel Deaconess Medical Centre, Harvard Medical School,
Boston - USA
- Feb 1997- Dic 1998 Research fellow, Katharine Dormandy Haemophilia Centre & Haemostasis Unit, Royal
Free Hospital, London – UK
- Nov 1996 Specialization in Hematology, University of Milan, Milan – Italy
- 1992-1996 Hematology fellow, IRCCS Maggiore Hospital, University of Milan, Milan - Italy
- 1991-1992 Resident in Medicine, San Paolo Hospital University of Milan, Milan - Italy
- 1991 Italian board of Internal Medicine
- 1991 Doctor of Medicine, Medical school of University of Milan, Milan - Italy
- 1990-1991 Transfusion center Scholarship, San Paolo Hospital, Milan - Italy
- 1987-1990 Internship, Department of Emergency and Department of Internal Medicine, San Paolo
Hospital, Milan - Italy
- 1982 Secondary school education, Natural Science High School Nedaye Azadi, Tehran -
Iran

MAJOR RESEARCH FIELDS

- Clinical and laboratory aspects of hereditary coagulation disorders (thrombophilia and hemophilia)
- Genotype and phenotype characterisation of patients affected with rare coagulation disorders and von Willebrand disease
- Biochemical characterisation of mutant recombinant proteins causing rare coagulation disorders and von Willebrand disease
- Implementation of a European working group finalised to the establishment of an on-line database for the collection of clinical, laboratory and therapeutic data related to patients affected by rare bleeding disorders (RBDs: fibrinogen deficiency, Factor (F) II, FV, FVII, FV+FVIII, FX, FXI and FXIII) (www.rbdd.eu). The project was awarded a grant by PHEA (Public Health Executive Agency)
- Implementation of an International database (www.rbdd.org) for the collection of clinical, phenotypic genotypic and therapeutic data related to patients affected by rare bleeding disorders
- Organization of a working group focusing on “Menorrhagia in women affected by rare bleeding disorders” (www.wrbd.org)
- Development of new techniques for prenatal diagnosis in early stage of pregnancy in women carriers of hemophilia or affected by one of the other rare coagulation disorders
- Gene mutation, transcription, translation and transport analysis of FVIII in hemophilic patients with inhibitors
- Implementation of a novel thrombotic thrombocytopenic purpura database for the collection of clinical, genetic and therapeutic data (www.tpdatabase.org)
- Basis research on molecular and immunological aspects of patients affected by autoimmune thrombotic thrombocytopenic purpura.
- ‘Next-generation’ DNA sequencing to study the genetic predisposition to thrombotic and haemorrhagic disorders (myocardial infarction, deep vein thrombosis and haemophilia)

PRIZES AND AWARDS

- 2014 Winner of the 6th edition of the “Grande Ippocrate” award for Scientific Research and Dissemination.
- 2013 Diagnosi prenatale: l'uso delle cellule fetali per la diagnosi genetica non invasiva in donne portatrici di emofilia. Italo Monzino Foundation, Milan – Italy (*Principal Investigator, 36 months*)
- 2013 Microangiopatie trombotiche. Italo Monzino Foundation, Milan – Italy (*Principal Investigator, 36 months*)
- 2013 Influence of aggregation extent of FVIII in pharmaceutical concentrates on their biochemical properties and coagulant efficacy. Funded by Biotest AG (*Principal Investigator, 24 months*)
- 2012 Costituzione di una rete lombarda per lo studio e il trattamento dei pazienti sottoposti a procedure di aferesi terapeutica. Regione Lombardia, Direzione generale Sanità - Italy (*Partner, 24 months*)
- 2012 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Esfahan Hemophilia center, Sayedalshohada Hospital, Esfahan – Iran. World Federation of Hemophilia (WFH) (*Principal Investigator, 36 months*)
- 2012 European Haemophilia Network (EUHANET). Commission of the European Union, The Executive Agency for Health and Consumers (EAHC) (*Workpackage leader, 36 months*)
- 2012 Prospective evaluation of the intensity of bleeding episodes in patients with coagulation factor XIII deficiency (PRO-RBDD). Funded by NovoNordisk, Denmark (*Principal Investigator, 36 months*)
- 2011 New risks factor for complex atherothrombotic diseases – role of von Willebrand factor and of the metalloprotease ADAMTS13. Fiera Foundation, Milan - Italy (*Principal Investigator, 17 months out of 72*)
- 2011 Discovery of genetic determinants of inhibitor development in hemophilia a by exome sequencing. Bayer Hemophilia Awards Program - Special project award (*Principal Investigator, 24 months*)
- 2011 Biochemical, conformational and functional characterization of a novel purified FVIII concentrate from BioTest: a comparative study. Funded by Biotest AG (*Principal Investigator, 24 months*)
- 2011 Multiplexed next-generation sequencing of the haemostatic exome in deep vein thrombosis. Cariplo Foundation, Milan - Italy (*Principal Investigator, 21 months*)
- 2010 Modello di integrazione tra attività di ricerca sperimentale e pratica clinica: l'approccio alle microangiopatie trombotiche. Regione Lombardia, Direzione generale Sanità - Italy (*Partner, 24 months*)
- 2010 Microangiopatie trombotiche. Italo Monzino Foundation, Milan – Italy (*Collaborator, 36 months*)
- 2010 Enlargement of the European network of the Rare Bleeding Disorders (EN-RBD). European Association of Hemophilia and Allied Disorders (EAHAD), Sheffield – UK (*Principal Investigator, 12 months*)
- 2010 Programma di lavoro del Presidio di coordinamento regionale per le coagulopatie congenite. Regione Lombardia, Direzione generale Sanità - Italy (*Principal Investigator, 36 months*)
- 2009 Inhibitor development in previously untreated patients (PUPs) or minimally blood component-treated patients (MBCTPS) when exposed to von Willebrand factor-containing factor VIII concentrates and to recombinant factor VIII concentrates: an international, multicentre, prospective, controlled, randomised, open label, clinical trial. Angelo Bianchi Bonomi Foundation, Milan – Italy (*Partner, 60 months*)
- 2009 Cellule fetali nel sangue materno. Una promettente tecnica non invasiva di diagnosi

- prenatale delle malattie genetiche. Paracelso Foundation, Milan – Italy (*Principal Investigator, 12 months*)
- 2009 Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan – Italy (*Principal Investigator, 36 months*)
- 2008 Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. PUR (ex FIRST) grant, University of Milan, Milan – Italy (*Principal Investigator, 12 months*)
- 2008 Menorrhagia and other gynecological problems in women affected by rare bleeding disorders. Laboratoire français du Fractionnement et des Biotechnologies (LFB) – France (*Principal Investigator, 12 months*)
- 2007 Establishment of a European Network of Rare Bleeding Disorders. Istituto Superiore di Sanità, Rome – Italy (*Principal Investigator, 24 months*)
- 2007 Meccanismi molecolari patogenetici nella carenza combinata dei fattori della coagulazione V e VIII (F5F8D). FIRST grant, University of Milan- Italy (*Principal Investigator, 12 months*)
- 2007 Biochemical and molecular characterization of the interaction between Von Willebrand Factor and ADAMTS-13: new hypotheses on physiopathogenesis of thrombotic microangiopathic diseases. PRIN grant, Italian Ministry of University and Research – Italy (*Principal Investigator, 24 months*)
- 2007 Establishment of an European Network of Rare Bleeding Disorders. Commission of the European Unit - Public Health Executive Agency (PHEA) (*Principal Investigator, 36 months*)
- 2007 Rare bleeding disorders: development of a European Registry and characterization of the molecular mechanisms. Telethon – Italy (*Collaborator, 36 months*)
- 2007 Thrombospondin-1 (TSP-1), ADAMTS13 and von Willebrand (VWF): role in the thrombotic thrombocytopenic purpura (TTP). Funded by Baxter – Italy (*Principal Investigator, 12 months*)
- 2006 Trombospondina-1 (TSP-1), ADAMTS13 e fattore di von Willebrand (VWF): ruolo nella porpora trombotica trombocitopenica (TTP). FIRST grant, University of Milan- Italy (*Principal Investigator, 12 months*)
- 2006 Markers genetici nella prevenzione farmacologica dell'ictus ischemico giovanile. Ricerca Finalizzata Ministry of Health – Italy (*Collaborator, 24 months*)
- 2006 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan – Italy and Hemostasis & Thrombosis unit, Hematology research center, Dastgheyb Hospital , Shiraz medical University of Science, Shiraz - Iran, World Federation of Hemophilia (WFH) (*Principal Investigator, 36 months*)
- 2006 Mantenimento ed implementazione di un Database Internazionale sulle malattie rare della coagulazione. Banca Fideuram (*Principal Investigator, una tantum*)
- 2005 Registro Internazionale sui pazienti affetti da Porpora Trombotica Trombocitopenica (TTP): caratterizzazione fenotipica e genotipica. FIRST grant, University of Milan- Italy (*Principal Investigator, 12 months*)
- 2005 Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan – Italy (*Principal Investigator, 36 months*)
- 2005 Molecular genetics of hereditary rare bleeding disorders in Indian population. Ministry of Foreign Affairs, General Directorate for Cultural Promotion and Co-operation – Italy (*Principal Investigator, 24 months*)
- 2004 Association between polymorphisms in gene encoding for inflammaton protein and juvenile myocardial infarction. COFIN grant, Italian Ministry of University and Research - Italy (*Collaborator, 24 months*)
- 2004 Sviluppo di nuovi test diagnostici quantitativi e funzionali della proteasi del fattore von Willebrand per la diagnosi delle malattie trombotiche microangiopatiche. IRCCS Maggiore Hospital, Milan - Italy (*Principal Investigator, 12 months*)
- 2003 Valutazione di polimorfismi genetici associati alla trombosi e farmacogenomica degli anticoagulanti con nuove tecnologie ad alta resa. IRCCS Maggiore Hospital, Milan – Italy (*Principal Investigator, 12 months*)

- 2003 Inflammation genes and development of myocardial infarction at a young age. Retrospective case-control study of 2000 cases and 2000 controls enrolled by 125 Italian Coronary Care Unit in eight years. Cariplo Foundation, Milan - Italy (*Principal Investigator, 12 months*)
- 2003 Phenotype and genotype characterization of recessively inherited coagulation disorders. Bayer Hemophilia Awards Program - Early career investigator award. (*Principal Investigator, 24 months*)
- 2003 Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. Telethon - Italy (*Collaborator, 36 months*)
- 2003 Clinical and molecular diagnosis of rare coagulation disorders. UniCredit Private Bank (*Principal Investigator, una tantum*)
- 2003 Membrane metalloproteinases involved in disorders of haemostasis. COFIN grant, Italian Ministry of University and Research - Italy (*Collaborator, 24 months*)
- 2002 Quantitative and functional assays of the VWF-cleaving protease (ADAMTS-13) for thrombotic thrombocytopenic purpura. Cariplo Foundation, Milan - Italy (*Principal Investigator, 12 months*)
- 2002 Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. COFIN grant, Italian Ministry of University and Research - Italy (*Collaborator, 24 months*)
- 2002 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and Nemazee Hospital, Shiraz - Iran. World Federation of Hemophilia (WFH) (*Principal Investigator, 48 months*)
- 2001 In vivo and in vitro studies of angiogenetic process by VEGF in patients by myocardial infarction. Cariplo Foundation, Milan - Italy (*Principal Investigator, 12 months*)
- 2001 Difetti autosomici recessivi della coagulazione del sangue: causa di carenza di fattori della coagulazione. Italo Monzino Foundation, Milan - Italy (*Principal Investigator, 24 months*)
- 2000 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and the Teheran Iman Khomeini Hospital Hemophilia Center, Tehran - Iran, awarded by World Federation of Hemophilia (WFH) (*Principal Investigator, 36 months*)
- 2000 Diagnosi prenatale e precoce delle malattie ereditarie. Ricerca Finalizzata Ministry of Health - Italy (*Principal Investigator, 12 months*)
- 2000 Prize awarded to young scientists, 16th Congress of the Italian Society Thrombosis and Hemostasis, Milan - Italy
- 1999 Young Investigator Award for best scientific communication, XV Congress of the Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET), Napoli, Italia
- 1998 Young Investigator Award for best scientific communication, 17th Congress of the International Society on Thrombosis and Haemostasis. Washington DC - USA
- 1998 Caratterizzazione molecolare della carenza della carenza di fattore X della coagulazione. Bando giovani ricercatori, University of Milan - Italy (*Principal Investigator, 24 months*)

MAJOR COMMITTEE ASSIGNMENTS

EAHAD executive committee member (feb 2015- present)

WFH World Federation of Hemophilia's liaison for ISTH to enhance collaboration and communication between the two organizations. (nov 2014 - present)

Member of the WFH International External Quality Assessment Scheme (IEQAS) committee (2014-2016)

Co- chair of International Society of Haemostasis and Thrombosis Scientific and Standardization Committee (SSC) on Factor VIII, Factor IX & Rare Coagulation

Disorders (Sept 2014 – Sept 2015)

Expert in the Health, Demographic Change, Wellbeing area in the Technical-Scientific Direction of the project "Rete IRCCS/DI per l'Europa", National Ministry of Public Health (March 2014 – present)

Chair of the VWD & Rare Bleeding Disorders Committee of the World Federation of Hemophilia (WFH) (April 2013 – present)

Member of the Executive Committee of the Board of the University professors in Internal Medicine (COLMED/09) (Mar 2013 – present)

Member of the review panel of the European Hematology Association (EHA)-International Society of Haemostasis and Thrombosis (ISTH) fellowship (Jan 2013 – present)

Member of the Educational Committee of the International Society of Haemostasis and Thrombosis (ISTH) (Nov 2012 – present)

Member of the Executive Committee of the World Federation of Hemophilia (WFH) (Oct 2012 – present)

Member of the WFH International Hemophilia Training Centre (IHTC) Committee (Oct 2012 - present)

Member of the Editorial Board of the Orphanet Journal of Rare diseases (OJRD) (Jun 2011 - present)

Member of the World Federation of Hemophilia (WFH) Research Committee (Oct 2010 - present)

Member of the VWD & Rare Bleeding Disorders Committee of the World Federation of Hemophilia (WFH) (Nov 2012 – April 2013)

Member of the Managing Board of Associazione Italiana Centri Emofilia (AICE) (Nov 2011 – Oct 2014)

Chair of International Society of Haemostasis and Thrombosis Scientific and Standardization Committee (SSC) on Factor VIII, Factor IX & Rare Coagulation Disorders (Sept 2010 – Sept 2014)

Member of the Medical Advisory Group of European Hemophilia Consortium (EHC) (Nov 2009 - present)

Co-Chair of the ISTH Scientific and Standardization Committee (SSC) on Factor VIII & Factor IX (Oct 2005 - Aug 2010)

Member of the Scientific Program Committee of European Hematology Association (EHA) (Jul 2006 - Jun 2007)

Member of the European Association for Haemophilia and Allied Disorders (EAHAD) (2008 – present)

Member of International Society of Haemostasis and Thrombosis (ISTH) (Jul 2005 – present)

Member of American Society of Hematology (ASH) (Jan 2005 – present)

Member of Società Italiana di Medicina Interna (SIMI) (July 2008 – present)

Member of Associazione Italiana Centri Emofilia (AICE) (Aug 2009 – present)

Member of Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET) (Jun 1998 – present)

ANNEXES

INVITED SPEAKER TO INTERNATIONAL CONGRESSES – LIST OF PUBLICATIONS

I hereby grant permission to handle my personal data in accordance with the Italian Legislative Decree 196/2003

Milano,

INVITED SPEAKER – INTERNATIONAL CONGRESSES

1. 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Helsinki, Finland, Feb 11-13, 2015. **Emerging therapies for rare bleeding disorders - FV, FX**
2. Highlights of the 19th Congress during the IV Pan Arab Hematology Congress and the XIII Saudi Society of Hematology Congress, Abu Dhabi, UAE, Feb 5-7, 2015. **1) Update on long-lasting clotting factor concentrates; 2) Acquired VWD and Hemophilia**
3. European Haemophilia Consortium Workshop on New Technologies in Haemophilia Treatment, Dublin, Ireland, Nov 21-23, 2014. **1) Regulatory Access in Europe for New Technologies in Haemophilia Treatment; 2) PEGylation/GlycoPEGylation technology**
4. International Society on Thrombosis and Haemostasis (ISTH) Educational Course, Moscow, Russia, Sep 17-19, 2014. **1) Inhibitors in hemophilia; 2) Overview on Rare Bleeding Disorders**
5. National Hemophilia update meeting, Bangalore, India, Jul 5-6, 2014. **1) RBD Registry – How India can participate; 2) Selection of Clotting factor concentrates and newer CFCs**
6. 60th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), Milwaukee, USA, 23-26 June, 2014. **Status of International Registries**
7. 19th EHA Congress - Educational session, Milan, Italy, Jun 12-15, 2014. **Rare bleeding disorders**
8. UK NEQAS for Blood Coagulation Annual Scientific Meeting, Sheffield, UK, Jun 4-5, 2014. **The future of coagulation factor replacement.**
9. World Federation of Hemophilia World Congress, Melbourne, Australia, May 11-15, 2014. **1) Introduction to clinical research design; 2) Clinical trials for market authorization of clotting factor concentrates - ISTH SSC recommendations**
10. International Hemophilia Congress of Turkiye, Istanbul, Turkey, April 18-21, 2014. **1) Future of rare bleeding diseases; 2) Inhibitors in Haemophilia and why the SIPPET study.**
11. International Plasma Protein Congress, Vienna, Austria, 11-12 March 2014. **Overview of new coagulation factor technologies.**
12. Irish Hemophilia Society, Long Lasting Technologies Within Haemophilia, Dublin, Ireland, November 22-24, 2013. **Impact of longer acting products on haemophilia care- the clinicians view**
13. Current Practices in Thrombosis and Hemostasis – 2013, Riyadh, Saudi Arabia, November 16- 18, 2013. **1) Future of coagulation factors replacement therapy, 2) Rare Bleeding Disorders**
14. 26th Annual Conference of European Haemophilia Consortium, Bucharest, Romania, October 4-6, 2013. **1) Rare bleeding disorders - an overview, 2) Orphan drugs, clinical trials and haemophilia**
15. 8th World Federation of Hemophilia Global Forum, Montreal, Canada September 26-27, 2013. **Clinicians perspective on market exclusivity for hemophilia products**
16. XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, June 29- July 4, 2013. **1) Master Class on Rare Bleeding Disorders, 2) Future of coagulation factor replacement therapy**
17. 2013 FASEB Science Research Conferences “Proteases in Hemostasis and Vascular Biology”, Nassau, The Bahamas, 2-7 June , 2013. **The ADAMTS13 metalloprotease in hemostasis**
18. European Directorate for the Quality of Medicines and Healthcare (EDQM) Symposium “Optimal use of clotting factors and immunoglobulins”, Wildbad Kreuth, Germany , 26-27 April 2013. **Innovative clotting factor concentrates**
19. The Sixth International and Eleven National Congress on Quality Improvement in Clinical Laboratory, Tehran, Iran, April 20-23, 2013. **Molecular diagnosis of hemophilia**
20. British Society of Hematology, Liverpool, UK, April 15-17, 2013. **Thrombotic Thrombocytopenic Purpura**
21. 6th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Warsaw, Poland, February 6-8, 2013. **1) PRO-RBDD project; 2) EN-RBD results on FXIII deficiency- present and future**
22. Women’s Health Issues in Thrombosis and Hemostasis (WHITH), Vienna, Austria, February 1-3, 2013. **Thrombotic microangiopathy (in women)**
23. Sixth International Conference of the Royal Medical Services, Amman, Jordan, November 19-22, 2012. **1) TTP treatment; 2) Rare bleeding disorders**
24. Advanced Course in Haemostasis & Thrombosis organized by the International Society on Thrombosis and Haemostasis in collaboration with the World Federation of Hemophilia and the Serbian Society of Haemostasis and Thrombosis, Belgrade, Serbia, November 7-9, 2012. **1) Challenges in the diagnosis and therapy of haemophilia; 2) A case of FX deficiency**
25. European Hemophilia Consortium (EHC) 2012 Annual Conference, Prague, Czech Republic, October 26-28,

2012. **1) Current approaches to prophylaxis in haemophilia A vs haemophilia B: similarities and differences; 2) Prenatal Diagnosis and Pre Implantation Genetic Diagnosis**
26. X Argentine Congress on Thrombosis and Hemostasis, Buenos Aires, Argentine, October 24-27. **1) Approach to the patient with muco-cutaneous bleeding; 2) Role of ADAMTS13 in microangiopathies**
 27. UK NEQAS for Blood Coagulation Annual Scientific Meeting, September 4-5, 2012. **Inherited Bleeding Disorders in Women**
 28. WFH 2012 World Congress in Paris, France, July 8-12, 2012. **1) New drugs, new problems; 2) How studies lead to ideas lead to studies: a scientific case; 3) Antenatal complications**
 29. 58th Meeting of the Scientific & Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH), Liverpool, UK, 27-30 June, 2012. **Translational approaches to TTP**
 30. International Society of Laboratory Hematology meeting, Nice, France, May 21-24, 2012 . **Update on Testing for Rare Bleeding Disorders**
 31. 1st Annual Meeting of the Taiwan Society of T&H, Taiwan, May 19-20, 2012. **1) RBDs Epidemiology. Diagnosis and treatment; 2) Diagnosis and treatment of VWD**
 32. American Society of Pediatric Hematology Oncology Meeting , New Orleans, USA, May 9-12, 2012. **Optimizing Care for Rare Bleeding Disorders Through Harmonization of National and International Databases**
 33. United Arab Emirates (UAE) Hematology Group, Abu Dhabi, United Arab Emirates, March 8-10, 2012. **Rare bleeding disorders**
 34. Saudi Society of Transfusion Medicine First International Conference, Jeddah, Saudi Arabia, March 5-8, 2012. **Rare bleeding disorders**
 35. 5th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Rome, Italy, February 22-24, 2012. **1) EAHAD working parties; 2) Factor VIII inhibitor: the most cogent unresolved issue in haemophilia**
 36. Gesellschaft fur Thrombose und Hamostaseforschung (GTH) "Unmet needs in rare bleeding disorders". St. Galle, Switzerland, February 2-4, 2012. **Characterising the epidemiology and management of rare bleeding disorders**
 37. EHC Round Table, Brussels, Belgium, December 7th, 2011. **Research in bleeding disorders: the importance of access to a choice of treatment for patients with Haemophilia**
 38. Bleeding disorders workshop. Birmingham, December 1 – 2, 2011. **Menorrhagia and bleeding.**
 39. WFH / GAP Masac Education Symposium, Johannesburg, South Africa, November 25-26, 2011. **1) Registries of rare bleeding disorders: why do we need them?, 2) Rare bleeding disorders diagnosis and treatment**
 40. Advanced Course in Thrombosis & Hemostasis, Cascais, Portugal, November 7-10, 2011. **Rare bleeding disorders**
 41. XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23-28, 2011. **1) Women and rare bleeding disorders, 2) EN-RBD next step: prospective data collection, 3) Why, how and what we expect from the WG on evaluation of clinical outcome, 4) First results of the Phase II TITAN trial**
 42. Rare Disease Working Group: Can Global Assays Address Current and Future Challenges in Therapeutic Monitoring of Hemophilia A?, Bethesda, USA, June 22-23, 2011. **Applicability of Global Assays to Clinical Scoring**
 43. 16th Congress of EHA, Londra, UK, 9-12 June 2010. **TTP therapy**
 44. 7th BIC Bari International Conference, Pugnochiuso, May 21-24, 2011. **Clinical implication of ADAMTS13-VWF interaction**
 45. Fostering international collaboration on rare diseases research: launch of the International Rare Disease Research Consortium (IRDiRC), National Institutes of Health, Bethesda, Maryland, April 5-8, 2011. **European Network of centres dealing with rare bleeding disorders**
 46. World Federation of Hemophilia's Global Research Forum, Montreal, Canada, March 22-23, 2011. **Are clinical trials in rare bleeding disorders different from those in hemophilia?**
 47. 4th International Symposium on Women's Health Issues in Thrombosis and Haemostasis, Berlin, Germany, February 4-6, 2011. **Post-Partum Hemorrhage in Women with Bleeding Disorders**
 48. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Geneva, Switzerland, February, 2-4, 2011. **1) Studies in collaboration with EAHAD. European network of rare bleeding disorders (EN-RBD), 2) Menorrhagia in women with rare bleeding disorders**
 49. Belgian Society on Thrombosis and Hemostasis annual meeting, Gent, Belgium, November 25-26, 2010. **Inherited bleeding disorders in women**
 50. 4^o Joint Advanced Educational Course on Thrombosis , Beirut, Lebanon, November 12th, 2010. **1) Diagnosis and treatment of Von Willebrand disease, 2) Thrombotic microangiopathies**

51. 23rd Annual EHC (European Hemophilia Consortium) Conference 2010, Lisbon, Portugal, October 22-24, 2010. **European network of rare bleeding disorders**
52. XXIX International Congress of the World Federation of Hemophilia 2010, Buenos Aires, Argentina, July 10-13, 2010. 1) **Prenatal diagnosis and PGD - Novel technologies and state of the art of PGD in different region of the world**, 2) **Clinical bleeding episodes in women with rare bleeding disorders: results from the European Network of Rare Bleeding Disorders (EN-RBD) project**, 3) **The European Network of Rare Bleeding Disorders (EN-RBD) project: results of 3-years analysis**
53. 21st International congress on thrombosis, Milan, Italy, July 6-9, 2010. **The genetic basis of congenital thrombotic thrombocytopenic purpura (TTP)**
54. 15th Congress of EHA, Barcellona, Spain, June 10-13, 2010. **Rare bleeding disorders - European registry**
55. 56th Annual SSC Meeting, Cairo, Egypt, May 22-25, 2010. 1) **Rare bleeding disorders**, 2) **The risk of recurrence of Thrombotic Thrombocytopenic Purpura in congenital and acquired ADAMTS13 deficient women**, 3) **Bleeding scores: rare bleeding disorders**, 4) **European network of RBDs (EN-RBD): Results of the collaboration at 3 years**, 5) **Bleeding scores in RBDs**, 6) **Definitions in rare bleeding disorders – Report of the working group**, 7) **The risk of miscarriage in women with rare bleeding disorders**, 8) **A growing RBD registry expanding into Middle East**
56. WFH bi-annual congress of the Royal Medical Services, Amman, Jordania, May1-5, 2010. 1) **VWD**; 2) **Rare bleeding disorders**
57. ISTH educational course on thrombosis and haemostasis, Shiraz, Iran, April 14-15, 2010. 1) **Inhibitor in haemophilia**, 2) **Rare bleeding disorder: Dx, Rx**
58. 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Edinburgh, Scotland, February 3-5, 2010. 1) **Rare bleeding disorders registry**; 2) **Rare bleeding disorders in search of a specific treatment**
59. XX Congress of International Society of Hematology, (ISH –EAD), Cairo, Egypt, October 10-13, 2009. 1) **Women's health and haemostasis**; 2) **Updates in diagnosis and management of TTP**
60. ATHN Data Summit, Chicago, USA, July 30-31, 2009. **European Network of Rare Bleeding Disorders (EN-RBD)**
61. XXII Congress of the International Society on Thrombosis and Haemostasis, Boston, USA, July 11-16, 2009. **Congenital and acquired TTP**
62. UK NEQAS Annual meeting 2009, Sheffield, UK, June 17-18, 2009. **Rare bleeding disorders**
63. Danubian League of Thrombosis and Hemostasis, Belgrade, Serbia, May 14-16, 2009. **Obstetric and gynaecological problems in women with inherited bleeding disorders**
64. European Directorate for the Quality of Medicines and Healthcare (EDQM) Symposium on "Optimal Clinical Use of Blood Components", Wildbad Kreuth, Germany, April 24-25, 2009. **Rare Bleeding disorders**
65. The 8th Novo Nordisk Annual Doctors and Nurses Symposium, Dublin Ireland, March 2-3, 2009. 1) **Thrombotic thrombocytopenic purpura**, 2) **Rare bleeding disorders, diagnostic and treatment guidelines**
66. 2nd Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Munich, February 26-27, 2009. 1) **Rare Diseases Registry**, 2) **Obstetric and gynaecological problems in women with inherited bleeding disorders**
67. XX Sabatina de Hematologia, Coimbra, Portugal, January 30th, 2009. **TTP and other thrombotic microangiopathies: congenital versus acquired**
68. EHC/EAHAD Launch of the European Principles of Care, Brussels, Belgium, January 27th, 2009. **Rare Bleeding Disorders Database (RBDD)**
69. Thrombosis and Hemostasis Update Conference, Riyadh, Saudi Arabia, November 11-12, 2008. **Common Genetic Abnormalities in Hemophilia**
70. XX Biotest Hemophilia Forum 2008, Athens, Greece, 31 October - 2 November, 2008. **Inhibitor development associated to FVIII gene defects**
71. Second Regional Meeting of Hematology, Beirut, Lebanon, October 23-25, 2008. 1) **The state-of-the-art management of rare bleeding disorders**, 2) **Differential diagnosis: microangiopathic anemia**, 3) **Hemophilia: the role of genetics in inhibitor development**
72. 21st Annual EHC (European Hemophilia Consortium) Conference 2008, Dublin, Ireland, September 12-14, 2008. **Reproduction and Hemophilia. An update on the science**
73. 54th Annual SSC meeting of ISTH, Wien, Austria, July 2-5, 2008. 1) **Menorrhagia in women affected by bleeding disorders** and 2) **Defining clinical severity of Rare Bleeding Disorders**
74. British Society for Haematology Annual Scientific meeting, incorporating the 6th Bi-Annual I-BFM Leukemia Symposium, Glasgow, UK, April 7-9, 2008. **Obstetric Hematology – Auto-immune disease in pregnancy**.
75. World Federation of Haemophilia World Congress, Istanbul, Turkey, June 1-6, 2008. **Genetics of Rare**

Bleeding Disorders

76. XXII Biotest Haemophilia Forum, Seefeld, Austria, March 13-16, 2008. **Common FVIII gene defects in Hemophilia and risk of inhibitor development**
77. Symposium of Hematology (Hemostasis and Thrombosis), Shiraz, Iran, February 18th, 2008. **Thrombotic microangiopathies**
78. 1st International and 6th National Congress of Quality Improvement in Clinical Laboratories, Tehran, Iran, February 13-16, 2008. **New techniques in prenatal diagnosis and Preimplantation in coagulation disorders**
79. ASH Annual Meeting, Atlanta, GA, USA, December 8-11, 2007. CLS Symposium. **A review of European and International RBD patient registries and current efforts to create a unified global system**
80. Irish Thrombosis and Vascular Biology Meeting, Trinity College, St.James Hospital, Dublin, Ireland, November 22nd, 2007. **ADAMTS-13 and TTP**
81. VIIth International Hemophilia Forum, Hammamet, Tunisia, October 25-28, 2007. **Common Genetics in Bleeding Disorders**
82. XXI Congress Of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July6-12, 2007. **Rare Bleeding Disorders. What do we expect from the international Registry?**
83. Treatment of Hemophilia in Developing Countries, Tehran, Iran, February 5-6, 2007. **Treatment of rare hereditary coagulation disorders in developing countries**
84. 2nd International Symposium on Women's Health Issues in Thrombosis and Haemostasis, Wien, Austria, February 2-4, 2007. **Inherited Bleeding Disorders**
85. Golden Jubilee International Conference "Emerging Trends in Haematology and Immunohaematology", Mumbai, India, 31 January - 3 February, 2007. **Rare coagulation factor deficiencies - International registry, Thrombotic thrombocytopenic purpura**
86. 12th Congress of European Hematology Association (EHA), Wien, Austria, June7-10, 2007. **Epidemiology of Coagulation Disorders**
87. 48th Annual Meeting and of the American Society of Hematology, Orlando, FL, USA, December 9-12, 2006. **Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura**
88. International Saudi Symposium on Hemostasis and Thrombosis, King Abdul Aziz University in Jeddah, Saudi Arabia, November 25-27, 2006. **Management of Women with Hereditary Bleeding Disorders, Thrombotic Thrombocytopenic Purpura**
89. Gordon Research Conferences: Hemostasis, Waterville, ME, USA, July 9-14, 2006. **Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura**
90. 52nd Annual Scientific and Standardization Committee Meeting, Oslo, Norway, 28 Jun-1 Jul, 2006. **RBDD project: state of the art, Menorrhagia in women affected by RBDs. Proposal of an International study**
91. 19th International Congress on Thrombosis, Tel Aviv, Israel, May 14-18, 2006. **From clinical and molecular characterisation to a treatment of rare bleeding disorders**
92. The First Regional Meeting of the Lebanese Society of Hematology and Blood Transfusion, Beirut, Lebanon, April 26-28, 2006. **1) Rare Bleeding disorders, menstrual abnormalities in women with hemostatic disorders, 2) Women with hereditary bleeding disorders, 3) TTP: VWF cleaving enzymes**
93. The 2nd International Conference of The Egyptian Society of Haematology & Research, Il Cairo, Egypt, February 7-9, 2006. **1) Genetic aspect of hemophilia, 2) Rare Hereditary Bleeding Disorders**
94. XIX Hemostasis and Thrombosis International Congress from the Latinoamerican Hemostasis and Thrombosis Cooperative Group, Viña del Mar, Chile, November 3-6, 2005. **1) Bleeding in Women, 2) The role of Adams13 in the new pathogenesis of TTP**
96. XXXth World Congress of the International Society of Haematology, Istanbul, Turkey, 28 September - 2 October, 2005. **1) The role of Adams-13 in the new physiopathogenesis of thrombotic thrombocytopenic purpura. 2) Treatment of congenital coagulation disorders in the third millenium. International Registry on Rare Bleeding Disorders (RBDs)**
97. Molecular Biology in Hemophilia and Thrombosis, University of Tehran, Imam Komeini Hospital, Tehran, Iran November 28-29, 2004. **International Registry on Rare Bleeding Disorders (RBDs), Rare Bleeding Disorders: two case reports**
98. Indian Society Thrombosis and Transfusion Medicine 45th Annual Conference, Vellore, India, November 18-20. 2004. **1) ADAMTS-13: a new assay in TTP patients, 2) New methods of assessment of Hemostasis Thrombin Generation Test**
99. 1st meeting in Thrombosis and Haemostasis, University Hospital, Khartoum, Sudan, 27 July - 3 August, 2004. **1) Hemophilia past, present and future e Inhibitor in Hemophilia, 2) Rare Coagulation Disorders, 3) When and how treat or prevent bleeding in Von Willebrand Disease**

100. 1st Saudi International Symposium on Bleeding Disorders, Saudi Arabia, February 21-22, 2004. **International registry of rare bleeding disorders**
101. The first International Symposium of Haemostasis & Thrombosis, Shiraz, Iran, 30 November - 1 December, 2003. **1) Molecular and clinical aspects of rare coagulation disorders in Iran and Diagnosis and 2) Management of thrombotic thrombocytopenic purpura**
102. V International Haemophilia Forum. Beirut, Lebanon, September 25-28, 2003. **Rare coagulation disorders**
103. World Federation of Hemophilia, Seville, Spain, May 24th, 2002. **Rare coagulation disorders – factor VII and factor X deficiencies**
104. World Federation Of Hemophilia, Montreal, Canada, May 16-21, 2000. **Congenital plasma coagulation defects**
105. XVI Congreso Internacional De Hemostasia Y Trombosis del Grupo CLATH, Lima, Peru, August 7-9, 1999. **Clinical manifestations and management of rare coagulation disorders**
106. National Hemophilia Workshop, Varanasi, India, January 22-24, 1999. **Rare inherited coagulation disorders, clinical features and management**

PUBLICATIONS

WITH NO IF: 16

TOTAL IF: 1274,096

Google Scholar H-index: 46

Scopus H-index: 41

Articles in peer-reviewed journals

1. Pastorelli L, Dozio E, Pisani LF, Boscolo-Anzoletti M, Vianello E, Munizio N, Spina L, Tontini GE, **Peyvandi F**, Corsi Romanelli MM, Vecchi M. Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. *Gastroenterol Res Pract*. 2015;2015:189341. doi: 10.1155/2015/189341. (IF 1.502)
2. Dimichele DM, Lacroix-Desmazes S, **Peyvandi F**, Srivastava A, Rosendaal FR; The Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Design of Clinical Trials for New Products in Hemophilia: Communication from the SSC of the ISTH. *J Thromb Haemost*. 2015 Feb 28. doi: 10.1111/jth.12882. [Epub ahead of print] (IF 5.55)
3. Palla R, **Peyvandi F**, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. *Blood*. 2015;125:2052-2061. (review IF 9.775)
4. **Peyvandi F**, Garagiola I. Treatment of Hemophilia in the Near Future. *Semin Thromb Hemost*. 2015 Feb 19. [Epub ahead of print] (review IF 3.693)
5. Ferrari B, Rossio R, **Peyvandi F**. Back pain: An old cause in a young adult. *Eur J Intern Med*. 2015 Feb 17. pii: S0953-6205(15)00037-0. doi: 10.1016/j.ejim.2015.02.002. [Epub ahead of print] (letter: IF 2.300:5=0.46)
6. Fischer K, Lassila R, **Peyvandi F**, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; on behalf of the EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. *Thromb Haemost* 2015 Jan 8;113(4). [Epub ahead of print] (IF 5.760)
7. Berger K, Schopohl D, Hilger A, Behr Gross ME, Giangrande P, **Peyvandi F**, Seitz R, Schramm W. Research in haemophilia B - approaching the request for high evidence levels in a rare disease. *Haemophilia*. 2015;21:4-20 (IF 2.468)
8. Franchi C, Salerno F, Conca A, Djade CD, Tettamanti M, Pasina L, Corrao S, Marengoni A, Marcucci M, Mannucci PM, Nobili A; **REPOSI Investigators**. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. *Eur J Intern Med*. 2014;25:847-52 (IF 2.300)
9. Ferrari B, Maino A, Lotta LA, Artoni A, Pontiggia S, Trisolini SM, Malato A, Rosendaal FR, **Peyvandi F**. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. *Orphanet J Rare Dis*. 2014;9:193 (IF 3.958)
10. Biguzzi E, Siboni SM, Ossola MW, Zaina B, Migliorini AC, **Peyvandi F**. Management of pregnancy in type 2B von Willebrand disease: case report and literature review. *Haemophilia*. 2015;21:e98-103 (IF 2.468)
11. Asselta R, Platé M, Robusto M, Borhany M, Guella I, Soldà G, Afrasiabi A, Menegatti M, Shamsi T, **Peyvandi F**, Duga S. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. *Thromb Haemost*. 2015;113:567-76 (IF 5.760)
12. Bucciarelli P, Siboni SM, Stufano F, Biguzzi E, Canciani MT, Baronciani L, Pagliari MT, La Marca S, Mistretta C, Rosendaal FR, **Peyvandi F**. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. *J Thromb Haemost*. 2015;13:228-36 (IF 5.550)
13. Rossio R, Lotta LA, Pontiggia S, Borsa Ghiringhelli N, Garagiola I, Ardissino G, Mikovic D, Cugno M, **Peyvandi F**. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. *Haematologica*. 2014 Nov 7. pii: haematol.2014.111062. [Epub ahead of print] (letter: IF 5.868:5=1.174)
14. Ferrari B, Cairo A, Pontiggia S, Mancini I, Masini L, **Peyvandi F**. Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient. *J Clin Apher*. 2014 Nov 4. doi: 10.1002/jca.21366. [Epub ahead of print] (IF 1.579)
15. Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, Santagostino E, Morfini M; **Italian Association of Haemophilia Centres (AICE) Working Party**. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. *Blood Transfus*. 2014;12:575-98 (IF 1.901)

16. Biguzzi E, Franchi F, Acaia B, Ossola W, Nava U, Paraboschi EM, Asselta R, **Peyvandi F**. Genetic background and risk of postpartum haemorrhage: results from an Italian cohort of 3219 women. *Haemophilia*. 2014;20:e377-83 (IF 2.468)
17. Franchi F, Biguzzi E, Stufano F, Siboni SM, Baronciani L, **Peyvandi F**. A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. *Thromb Res*. 2014;134:1316-22 (IF 2.427)
18. Mannucci PM, Nobili A; **REPOSI Investigators**. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. *Intern Emerg Med*. 2014;9:723-34 (IF 2.410)
19. Tripodi A, Padovan L, Testa S, Legnani C, Chantarangkul V, Scalabrino E, Ludovici S, Bassi L, **Peyvandi F**. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. *Clin Chem Lab Med*. 2015;1;53:265-73 (IF 2.955)
20. Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, Pasina L, Franchi C, Kamal Eldin T, Marengoni A, Salerno F, Marcucci M, Mannucci PM, Nobili A; **REPOSI Investigators**. Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. *Eur J Intern Med*. 2014;25:617-23 (IF 2.300)
21. Cugno M, Tedeschi A, Siboni SM, Stufano F, Depetri F, Franchi F, Griffini S, **Peyvandi F**. Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. *Exp Hematol Oncol*. 2014;4:3:15 (IF 4.93)
22. Makris M, Calizzani G, Fischer K, Gatt A, Gilman E, Hollingsworth R, Lambert T, Lassila R, Mannucci PM, **Peyvandi F**, Windyga J. The European Haemophilia Network (EUHANET). *Blood Transfus*. 2014;12 Suppl 3:s515-8 (review IF 1.901)
23. Abbonizio F, Giampaolo A, Coppola A; **Italian Association of Haemophilia Centres**, Arcieri R, Hassan HJ. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. *Haemophilia*. 2014;20:e243-50 (IF 2.468)
24. O'Mahony B, **Peyvandi F**, Bok A. Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe? *Haemophilia*. 2014;20:455-8 (editorial: IF 3.170:5=0.634)
25. **Peyvandi F**, Rosendaal FR, O'Mahony B, Mannucci PM. Reply to: The importance and challenge of pediatric trials of hemophilia drugs. *Nat Med*. 2014 7;20:466 (IF 0)
26. Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, **Peyvandi F**, Rodeghiero F, Mannucci PM. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease: a prospective cohort study of 796 cases. *Blood*. 2014;123:4037-44 (IF 9.060)
27. **Peyvandi F**, Farrugia A, Iorio A, Key NS, Srivastava A. Joint WFH-ISTH session: issues in clinical trial design. *Haemophilia*. 2014;20 Suppl 4:137-44 (review IF 3.170)
28. James P, Salomon O, Mikovic D, **Peyvandi F**. Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. *Haemophilia*. 2014;20 (Suppl 4):71-5 (review IF 3.170)
29. Mancini I, Valsecchi C, Lotta LA, Deforche L, Pontiggia S, Bajetta M, Palla R, Vanhoorelbeke K, **Peyvandi F**. FRET-S-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. *Thromb Haemost*. 2014;17:112 (IF 5.044)
30. Makris M, **Peyvandi F**. Assaying FVIII activity: one method is not enough, and never was. *Haemophilia*. 2014;20:301-3 (editorial: IF 3.170:5=0.634)
31. Tripodi A, Capaccio P, Pignataro L, Chantarangkul V, Menegatti M, Bamonti F, Clerici M, De Giuseppe R, **Peyvandi F**. Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. *Thromb Res*. 2014;133:1130-4 (IF 3.133)
32. Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, **Peyvandi F**, Bertelli C, Valenti L, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. *J Hepatol*. 2014;61:148-54 (IF 9.858)
33. Abdul-Kadir R, McLintock C, Ducloy AS, El-Refaey H, England A, Federici AB, Grotegut CA, Halimeh S, Herman JH, Hofer S, James AH, Kouides PA, Paidas MJ, **Peyvandi F**, Winikoff R. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. *Transfusion*. 2014;54:1756-68 (IF 3.526)
34. Siboni SM, Biguzzi E, Pasta G, Mannucci PM, Mistretta C, Fantini NN, Solimeno LP, **Peyvandi F**. Management of orthopaedic surgery in rare bleeding disorders. *Haemophilia*. 2014;20:693-701 (IF 3.170)
35. Franchini M, Coppola A, Rocino A, Zanon E, Morfini M; Italian Association of Haemophilia Centers AICE Working Group, Accorsi A, Aru AB, Biasoli C, Cantori I, Castaman G, Cesaro S, Ciabatta C, De Cristofaro R, Delios G, Di Minno G, D'Incà M, Dragani A, Ettore CP, Gagliano F, Gamba G, Gandini G, Giordano P, Giuffrida G, Gresele P, Latella C, Luciani M, Margaglione M, Marietta M, Mazzucconi MG, Messina M,

- Molinari AC, Notarangelo LD, Oliovecchio E, **Peyvandi F**, Piseddu G, Rossetti G, Rossi V, Santagostino E, Schiavoni M, Schinco P, Serino ML, Tagliaferri A, Testa S. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. *Haemophilia*. 2014;20:e128-35 (IF 3.170)
36. Boccalandro E, Pasta G, Mannucci PM, Santagostino E, **Peyvandi F**, Seuser A, Mancuso ME, Solimeno LP. Integrated postural analysis in children with haemophilia. *Haemophilia*. 2014;20:263-7 (IF 3.170)
 37. **Peyvandi F**, Rosendaal FR, O'Mahony B, Mannuccio Mannucci P. Pediatric requirements in Europe stymie help for hemophilia. *Nat Med*. 2014;20:117 (opinion: IF 24.302)
 38. Menegatti M, Vangone A, Palla R, Milano G, Cavallo L, Oliva R, De Cristofaro R, **Peyvandi F**. A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. *Thromb Res*. 2014;133:481-7 (IF 2.799)
 39. Lotta LA, Valsecchi C, Pontiggia S, Mancini I, Cannavò A, Artoni A, Mikovic D, Meloni G, Peyvandi F. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2014 Mar;12:329-36 (IF 6.081)
 40. Sharief LT, Lawrie AS, Mackie IJ, Smith C, **Peyvandi F**, Kadir RA. Changes in factor XIII level during pregnancy. *Haemophilia*. 2014 Mar;20:144-148 (IF 3.170)
 41. Borhany M, Handrkova H, Cairo A, Schroeder V, Fatima N, Naz A, Amanat S, Shamsi T, **Peyvandi F**, Kohler HP. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. *Haemophilia*. 2014;20:568-74 (IF 3.170)
 42. Martinelli I, Bucciarelli P, Artoni A, Fossali EF, Passamonti SM, Tripodi A, **Peyvandi F**. Anticoagulant treatment with rivaroxaban in severe protein s deficiency. *Pediatrics* 2013;132:e1435-9 (IF 5.119)
 43. Kadir RA, Davies J, Winikoff R, Pollard D, **Peyvandi F**, Garagiola I, Pabinger I, Federici AB. Pregnancy complications and obstetric care in women with inherited bleeding disorders. *Haemophilia* 2013;19 (Suppl 4):1-10 (review IF 3.170)
 44. **Peyvandi F**, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. *Blood* 2013;122:3423-31 (review IF 9.060)
 45. Vucelić D, Miković D, Rajić Z, Savić N, Budisin Z, Antonijević NM, Obradović S, Jevtić D, Palla R, Valsecchio C, **Peyvandi F**. Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. *Srp Arh Celok Lek*. 2013 ;141:466-74 (IF 0.228)
 46. Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, Franchi C, Marengoni A, Salerno F, Corrao S, Violi F, Mannucci PM; **REPOSI Investigators**. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. *Eur J Intern Med*. 2013;24:800-6 (IF 2.049)
 47. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, **Peyvandi F**. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. *Haemophilia*. 2014;20:147-53 (IF 2.597)
 48. Siboni SM, Biguzzi E, Solimeno LP, Pasta G, Mistretta C, Mannucci PM, **Peyvandi F**. Orthopaedic surgery in patients with von Willebrand disease. *Haemophilia*. 2014;20:133-40 (IF 2.597)
 49. Franchi F, Biguzzi E, Martinelli I, Bucciarelli P, Palmucci C, D'Agostino S, **Peyvandi F**. Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. *Thromb Res*. 2013;132:e152-7 (IF 2.799)
 50. **Peyvandi F**, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. *Semin Thromb Hemost*. 2013;39:579-84. (review IF 4.216)
 51. **Peyvandi F**, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. *J Thromb Haemost*. 2013;11 Suppl 1:84-98 (review IF 6.081)
 52. Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, **Peyvandi F**, van Heerde WL. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. *Thromb Res*. 2013;132:256-62 (IF 2.440)
 53. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, Gatti L, Mannucci PM, **Peyvandi F**. Global coagulation in myeloproliferative neoplasms. *Ann Hematol*. 2013;92:1633-9 (IF 2.866)
 54. Scaglione GL, Lancellotti S, Pap M, De Spirito M, Maiorana A, Baronciani L, Pagliari MT, Arcovito A, Di Stasio E, **Peyvandi F**, De Cristofaro R. The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress. *J Thromb Haemost*. 2013;11:1688-98. (IF 5.731)
 55. **Peyvandi F**, Mannucci PM, Valsecchi C, Pontiggia S, Farina C, Retzios AD. ADAMTS13 content in plasma-derived factor VIII/ von willebrand factor concentrates. *Am J Hematol*. 2013;88:895-8. (IF 4.671)
 56. Musallam KM, Rosendaal FR, Zaatari G, Soweid A, Hoballah JJ, Sfeir PM, Zeineldine S, Tamim HM, Richards T, Spahn DR, Lotta LA, **Peyvandi F**, Jamali FR. Smoking and the Risk of Mortality and Vascular

- and Respiratory Events in Patients Undergoing Major Surgery. *JAMA Surg.* 2013;148:755-62. (IF 4.420)
57. Musallam KM, Porter JB, Sfeir PM, Tamim HM, Richards T, Lotta LA, **Peyvandi F**, Jamali FR. Raised haematocrit concentration and the risk of death and vascular complications after major surgery. *Br J Surg.* 2013 ;100:1030-6 (IF 4.839)
 58. Musallam KM, Jamali FR, Rosendaal FR, Richards T, Spahn DR, Khavandi K, Barakat I, Demoss B, Lotta LA, **Peyvandi F**, Sfeir PM. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. *Anemia.* 2013;2013:206829. doi: 10.1155/2013/206829. (IF 0)
 59. van Geffen M, Mathijssen NC, Holme PA, Laros-van Gorkom BA, van Kraaij MG, Masereeuw R, **Peyvandi F**, van Heerde WL. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. *Thromb Res.* 2013;132:116-22. (IF 2.440)
 60. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, Marengoni A, Salerno F, Corrao S, Mannucci PM; **REPOSI Investigators**. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med.* 2013;8:509-20 (IF 2.350)
 61. Lotta LA, Tuana G, Yu J, Martinelli I, Wang M, Yu F, Passamonti SM, Pappalardo E, Valsecchi C, Scherer SE, Hale Iv W, Muzny DM, Randi G, Rosendaal FR, Gibbs RA, **Peyvandi F**. Next-generation sequencing study finds an excess of rare, coding single nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. *J Thromb Haemost.* 2013;11:1228-39 (IF 5.731)
 62. Castaman G, Goodeve A, Eikenboom J; **European Group on von Willebrand Disease**. Principles of care for the diagnosis and treatment of von Willebrand disease. *Haematologica.* 2013;98:667-74. (IF 5.935)
 63. Pagliari MT, Baronciani L, Garcia Oya I, Solimando M, La Marca S, Cozzi G, Stufano F, Canciani MT, **Peyvandi F**. A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation cause exon 26 skipping in four patients with von Willebrand disease (2A/IIIE). *J Thromb Haemost.* 2013;11:1251-9 (IF 5.731)
 64. Lotta LA, Maino A, Tuana G, Rossio R, Lecchi A, Artoni A, **Peyvandi F**. Prevalence of disease and relationships between laboratory phenotype and bleeding severity in platelet primary secretion defects. *PLoS One.* 2013;8:e60396 (IF 4.092)
 65. **Peyvandi F**. Epidemiology and treatment of congenital fibrinogen deficiency. *Thromb Res.* 2012;130 Suppl 2:S7-11 (IF2.440)
 66. Lotta LA, Wu HM, Musallam KM, **Peyvandi F**. The emerging concept of residual ADAMTS13 activity in ADAMTS-13-deficient thrombotic thrombocytopenic purpura. *Blood Rev.* 2013; 27:71-6 (IF 5.355)
 67. Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, **Peyvandi F**, Karimi M. Comparison of Thrombin Generation Assay with Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With rare Bleeding Disorders. *Clin Appl Thromb Hemost.* 2013;20:637-644 (IF 1.332)
 68. Marengoni A, Nobili A, Pirali C, Tettamanti M, Pasina L, Salerno F, Corrao S, Iorio A, Marcucci M, Franchi C, Mannucci PM; **REPOSI Investigators**. Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. *Gerontology.* 2013;59:307-15 (IF 2.681)
 69. Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, **Peyvandi F**. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. *Thromb Haemost.* 2013; 109:488-96 (IF 5.044)
 70. Vucelić D, Rajić Z, Savić N, Miković D, Budisin Z, Antonijević NM, Obradović S, Jevtić D, Bettoni G, Casoli G, **Peyvandi F**. Clinical experience in treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome with 28 patients. *Acta Chir Iugosl.* 2013;60:29-38 (IF0)
 71. Rosendaal FR, **Peyvandi F**. Pediatric stroke and ADAMTS genes. *Blood.* 2012;120:5097-8 (commentary: IF 9.898:5=1.9796)
 72. Musallam KM, Khalife M, Sfeir PM, Faraj W, Safadi B, Abi Saad GS, Abiad F, Hallal A, Alwan MB, **Peyvandi F**, Jamali FR. Postoperative Outcomes After Laparoscopic Compared With Open Splenectomy. *Ann Surg.* 2013;257:1116-23 (IF 7.492)
 73. Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, **Peyvandi F**. A comparative evaluation of a new automated assay for von Willebrand factor activity. *Haemophilia.* 2013;19: 338-42 (IF 2.597)
 74. Franchi C, Nobili A, Mari D, Tettamanti M, Djade CD, Pasina L, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM, **REPOSI Investigators**. Risk factors for hospital readmission of elderly patients. *Eur J Intern Med.* 2013;24:45-51 (IF 2.000)
 75. Lotta LA, Degasperi E, Aghemo A, Ferrari B, **Peyvandi F**, Colombo M. Treatment of chronic hepatitis C with pegylated interferon- α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. *Transfus Med.* 2013;23:66-8 (letter: IF 1.140:5 = 0.228)
 76. Garagiola I, Mortarino M, Semprini AE, **Peyvandi F**. Reproductive care in human immunodeficiency virus serodiscordant couples with haemophilia. *Blood Transfus.* 2013;11:469-70 (letter: IF 2.099: 5 = 0.420)

77. Rossio R, Ferrari B, Cairo A, Mancini I, Pisapia G, Palazzo G, **Peyvandi F**. Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. *Blood Transfus.* 2013; 11:241-4 (IF 2.099)
78. Rubattu S, Giusti B, Lotta LA, **Peyvandi F**, Cotugno M, Stanzione R, Marchitti S, Palombella AM, Di Castro S, Rasura M, Mannucci PM, Volpe M. Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. *Eur J Intern Med.* 2013;24:80-2 (IF 2.00)
79. Lotta LA, Wu HM, Cairo A, Bentivoglio G, **Peyvandi F**. Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. *Blood Cells Mol Dis.* 2013;50:59-60. (letter: IF 2.351:5 = 0.470)
80. Lotta LA, Martinelli I, **Peyvandi F**. Prothrombin mutation conveying antithrombin resistance. *N Engl J Med.* 2012;367:1069. (letter: IF 53.298:5 = 10.660)
81. **Peyvandi F**, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; for the Project on Consensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. *J Thromb Haemost.* 2012;10:1938-43. (IF 5.731)
82. **Peyvandi F**, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. *Haemophilia.* 2012;18 Suppl 4:148-53. (IF 2.597)
83. Lucas G, Lluís-Ganella C, Subirana I, Musameh MD, Gonzalez JR, Nelson CP, Sentí M; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Schwartz SM, Siscovick D, O'Donnell CJ, Melander O, Salomaa V, Purcell S, Altshuler D, Samani NJ, Kathiresan S, Elosua R. Hypothesis-based analysis of gene-gene interactions and risk of myocardial infarction. *PLoS One.* 2012;7:e41730. (IF: 4.092)
84. Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, Kraft P, Chen R, Kallberg HJ, Kurreeman FA; Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction Genetics Consortium, Kathiresan S, Wijmenga C, Gregersen PK, Alfredsson L, Siminovitch KA, Worthington J, de Bakker PI, Raychaudhuri S, Plenge RM. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. *Nat Genet.* 2012;44:483-9. (IF 35.532)
85. Solimando M, Baronciani L, La Marca S, Cozzi G, Asselta R, Canciani MT, Federici AB, **Peyvandi F**. Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. *Am J Hematol.* 2012;87:870-4. (IF 4.671)
86. Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, Mancini I, Musallam KM, Rosendaal FR, **Peyvandi F**. ADAMTS13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2012;10:1556-65. (IF 5.731)
87. Bafunno V, Santacroce R, Chetta M, **Peyvandi F**, Sessa F, Chinni E, Longo V, Margaglione M. Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. *Haemophilia.* 2012;18:1003-7. (IF 2.597)
88. **Peyvandi F**, Klamroth R, Carcao M, Federici AB, Di Minno G, Jiménez-Yuste V, Rodríguez Merchán EC. Management of bleeding disorders in adults. *Haemophilia.* 2012;18 (Suppl 2):24-36. (review: IF 2.597)
89. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, **Peyvandi F**, Cheung B, Machin SJ; on behalf of British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol.* 2012;158:323-35. (IF 4.941)
90. Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJ, **Peyvandi F**, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. *J Matern Fetal Neonatal Med.* 2012;25:2322-5 (IF 1.495)
91. **Peyvandi F**. Willebrand disease. *Haemophilia.* 2012;18 (Suppl 2):1. (editorial: IF 2.597:5=0.519)
92. Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, **Peyvandi F**. Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura. *Blood.* 2012;120:440-8. (IF 9.898)
93. **Peyvandi F**, Biguzzi E, Franchi F, Bucciarelli P, Acaia B, Zaina B, Musallam KM. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. *J Thromb Haemost.* 2012;10:1451-3. (letter: IF 5.731: 5 = 1.146)
94. Mancini I, Valsecchi C, Palla R, Lotta LA, **Peyvandi F**. Measurement of anti-ADAMTS13 neutralising autoantibodies: a comparison between CBA and FRET assays. *J Thromb Haemost.* 2012;10:1439-42. (letter IF 5.731:5 = 1.146)
95. Cataland SR, **Peyvandi F**, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G,

- Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. *Am J Hematol*. 2012;87:430-2. (letter IF 4.671:5 = 0.934)
96. **Peyvandi F**, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolničar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR; ON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD) GROUP. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. *J Thromb Haemost*. 2012;10:615-621. (IF 5.731)
 97. Stufano F, La Marca S, Pontiggia S, Musallam KM, **Peyvandi F**. Von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2012;10:728-30. (letter IF 5.731:5 = 1.146)
 98. Lotta LA, Mancini I, Tuana G, Musallam KM, **Peyvandi F**. Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. *J Thromb Thrombolysis*. 2012;34:416-8. (IF 1.985)
 99. Karimi M, Vafafar A, Haghpanah S, Payandeh M, Eshghi P, Hoofar H, Afrasiabi A, Gerdabi J, Ardeshiri R, Menegatti M, **Peyvandi F**. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. *Haemophilia*. 2012;18:211-5. (IF 2.597)
 100. Lotta LA, Wang M, Yu J, Martinelli I, Yu F, Passamonti SM, Consonni D, Pappalardo E, Menegatti M, Scherer SE, Lewis LL, Akbar H, Wu Y, Bainbridge MN, Muzny DM, Mannucci PM, Gibbs RA, **Peyvandi F**. Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes. *BMC Med Genomics*. 2012;5:7. (IF 3.690)
 101. Mannucci PM, Gringeri A, Santagostino E, **Peyvandi F**. Factor VIII inhibitor and source of replacement therapy. *Blood Transfus*. 2012;10:112-3. (letter IF 2.099:5 = 0.420)
 102. Siboni SM, Zanon E, Sottilotta G, Consonni D, Castaman G, Mikovic D, Biondo F, Tagliaferri A, Iorio A, Mannucci PM, **Peyvandi F**. Central nervous system bleeding in patients with rare bleeding disorders. *Haemophilia*. 2012;18:34-8. (IF 2.597)
 103. Eshghi P, Cohan N, Lak M, Naderi M, **Peyvandi F**, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. *Clin Appl Thromb Hemost*. 2012;18:100-3. (IF 1.332)
 104. Paraboschi EM, Kayiran SM, Ozbek N, Gürakan B, **Peyvandi F**, Guella I, Duga S, Asselta R. Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency. *Haemophilia*. 2012;18:205-10. (IF 2.597)
 105. Shapiro AD, Soucie JM, **Peyvandi F**, Aschman DJ, Dimichele DM; UDC Rare Bleeding and Clotting Disorders Working Group and the European Network Rare Bleeding Disorders Database. Knowledge and therapeutic gaps a public health problem in the rare coagulation disorders population. *Am J Prev Med*. 2011;41(Suppl 4):S324-31. (IF 4.044)
 106. **Peyvandi F**, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. *Semin Fetal Neonatal Med*. 2011;16:311-7. (review: IF 3.915)
 107. Mariani M, Cairo A, Palla R, Lotta LA, Consonni D, Rovati A, Trisolini S, **Peyvandi F**. B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. *Thromb Res*. 2011;128:590-2. (letter IF 2.440:5 = 0.488)
 108. Mortarino M, Garagiola I, Lotta LA, Siboni SM, Semprini AE, **Peyvandi F**. Non-invasive tool for foetal sex determination in early gestational age. *Haemophilia*. 2011;17:952-6. (IF 2.597)
 109. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM, Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martínez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancáková A, Stirrups K, Swift AJ, Syvänen AC, Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B; DIAGRAM Consortium; GIANT Consortium; MuTHER Consortium; CARDIoGRAM Consortium; C4D Consortium, Ongen H, Mälarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Ríos M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Sedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermizakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the

- pathophysiology of type 2 diabetes. *Diabetes*. 2011;60:2624-34. (IF 8.286)
110. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Lee CA, Martínez-Perez O, McLintock C, **Peyvandi F**, Philipp C, Wilkinson J, Winikoff R. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. *Eur J Obstet Gynecol Reprod Biol*. 2011;158:124-34. (review: IF 1.974)
 111. Guella I, Duga S, Ardissino D, Merlini PA, **Peyvandi F**, Mannucci PM, Asselta R. Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population. *Thromb Haemost*. 2011;106:655-64. (IF 5.044)
 112. Muszbek L, Bagoly Z, Cairo A, **Peyvandi F**. Novel aspects of factor XIII deficiency. *Curr Opin Hematol*. 2011;18:366-72. (review: IF 4.520)
 113. Haghpanah S, Sahraian M, Afrasiabi A, Enayati S, **Peyvandi F**, Karimi M. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. *Haemophilia*. 2011;17:820-1. (letter IF 2.597:5 = 0.519)
 114. Lotta LA, Lombardi R, Mariani M, Lancellotti S, De Cristofaro R, Hollestelle MJ, Canciani MT, Mannucci PM, **Peyvandi F**. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. *J Thromb Haemost*. 2011;9:1744-51. (IF 5.731)
 115. Bornikova L, **Peyvandi F**, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. *J Thromb Haemost*. 2011;9:1687-704. (review: IF 5.731)
 116. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. *PLoS Genet*. 2011;7:e1002260. (IF 8.694)
 117. Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB; **SSC sub-committee on von Willebrand factor of ISTH**. Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182). *J Thromb Haemost*. 2011;9:1638-40. (IF 5.731)
 118. Lancellotti S, De Filippis V, Pozzi N, Oggianu L, Rutella S, Scaglione GL, Maset F, **Peyvandi F**, Mannucci PM, De Cristofaro R. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13. *J Thromb Haemost*. 2011;9:1620-7. (IF 5.731)
 119. Ardissino D, Berzuini C, Merlini PA, Mannucci PM, Surti A, Burti N, Voight B, Tubaro M, **Peyvandi F**, Spreafico M, Celli P, Lina D, Notarangelo MF, Ferrario M, Fève R, Casari G, Galli M, Ribichini F, Rossi ML, Bernardi F, Marziliano N, Zoncin P, Mauri F, Piazza A, Foco L, Bernardinelli L, Altshuler D, Kathiresan S; Italian Atherosclerosis, Thrombosis and Vascular Biology Investigators. Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. *J Am Coll Cardiol*. 2011;58:426-34. (IF 14.156)
 120. Mahmoodi M, **Peyvandi F**, Afrasiabi A, Ghaffarpasand F, Karimi M. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. *Blood Coagul Fibrinolysis*. 2011;22:396-401. (IF 1.238)
 121. **Peyvandi F**, Garagiola I, Mortarino M. Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. *Haemophilia*. 2011;17 (Suppl 1):14-7. (IF 2.597)
 122. **Peyvandi F**, Garagiola I, Menegatti M. Gynecological and obstetrical manifestations of inherited bleeding disorders in women. *J Thromb Haemost*. 2011;9 (Suppl 1):236-45. (review: IF 5.731)
 123. **Peyvandi F**, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. *Blood Transfus*. 2011;9 (Suppl 2):s3-8. (review: IF 2.099)
 124. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Mühleisen TW, Muhlestein JB, Münzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nöthen MM, Olivieri O, Patel RS, Patterson CC, Peters A, **Peyvandi F**, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schäfer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivanathan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang

- WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Wittman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, März W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J; CARDIoGRAM Consortium, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43:333-8. (IF 35.532)
125. Lawrie AS, Mackie IJ, Machin SJ, **Peyvandi F**. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. *Haemophilia.* 2011;17:252-6. (IF 2.597)
126. De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, Mauri F, **Peyvandi F**, Lina D, Kathiresan S, Bernardinelli L, Ardissino D; Gruppo Italiano Aterosclerosi. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. *Atherosclerosis.* 2011;214:397-403. (IF 3.794)
127. Palla R, Valsecchi C, Bajetta M, Spreafico M, De Cristofaro R, **Peyvandi F**. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. *Thromb Haemost.* 2011;105:381-5. (letter IF 5.044:5 = 1.009)
128. **Peyvandi F**, Menegatti M, Siboni SM. Post-partum hemorrhage in women with rare bleeding disorders. *Thromb Res.* 2011;127 (Suppl 3):S116-9. (IF 2.440)
129. Lotta LA, **Peyvandi F**. Addressing the complexity of cardiovascular disease by design. *Lancet.* 2011;377:356-8. (commentary IF 38.278:5 = 7.656)
130. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet.* 2011;377:383-92. (IF 38.278)
131. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, **Peyvandi F**. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. *Br J Haematol.* 2010;151:488-94. (IF 4.942)
132. **Peyvandi F**, Palla R, Lotta LA. Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. *Haematologica.* 2010;95:1444-7 (commentary IF 6.532:5 = 1.306)
133. Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, **Peyvandi F**. Factor XIII - an under diagnosed deficiency - are we using the right assays? *J Thromb Haemost.* 2010;8:2478-82. (IF 5.439)
134. Guella I, Asselta R, Ardissino D, Merlini PA, **Peyvandi F**, Kathiresan S, Mannucci PM, Tubaro M, Duga S. Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. *J Lipid Res.* 2010;51:3342-9. (IF 6.115)
135. Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, **Peyvandi F**, Kathiresan S, Ardissino D. The association of factor V Leiden with myocardial infarction is replicated in 1,880 patients with premature disease. *J Thromb Haemost.* 2010;8: 2116-21. (IF 5.439)
136. Feys HB, Vandeputte N, Palla R, **Peyvandi F**, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2010;8:2053-62. (IF 5.439)
137. Lawrie AS, Green L, Canciani MT, Mackie IJ, **Peyvandi F**, Scully MA, Machin SJ. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. *Vox Sang.* 2010;99:232-8. (IF 3.292)
138. Lotta LA, Giusti B, Saracini C, Vestri A, Volpe M, Rubattu S, **Peyvandi F**. No association between chromosome 12p13 single nucleotide polymorphisms and early-onset ischemic stroke. *J Thromb Haemost.* 2010;8:1858-60. (letter IF 5.439:5 = 1.088)
139. Mannucci PM, Lotta LA, **Peyvandi F**. Genome-wide association studies in myocardial infarction and coronary artery disease. *J Teh Univ Heart Ctr* 2010;5:116-21. (IF -)
140. Giusti B, Saracini C, Bolli P, Magi A, Martinelli I, **Peyvandi F**, Rasura M, Volpe M, Lotta LA, Rubattu S, Mannucci PM, Abbate R. Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. *Thromb Haemost.* 2010;104:231-42. (IF 4.701)
141. **Peyvandi F**, Hollestelle MJ, Palla R, Merlini PA, Feys HB, Vanhoorelbeke K, Lenting PJ, Mannucci PM. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. *J Thromb Haemost.* 2010;8:1653-6. (letter IF 5.439:5 = 1.088)
142. **Peyvandi F**, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2010;8:631-40. (review: IF 5.439)

143. Asselta R, Rimoldi V, Guella I, Soldà G, De Cristofaro R, **Peyvandi F**, Duga S. Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. *Blood*. 2010;115:2065-72. (IF 10.588)
144. Bafunno V, Santacroce R, Chetta M, D'Andrea G, Pisanelli D, Sessa F, Trotta T, Tagariello G, **Peyvandi F**, Margaglione M. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. *Haemophilia*. 2010;16:469-73. (IF 2.364)
145. Lancellotti S, De Filippis V, Pozzi N, **Peyvandi F**, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxyxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. *Free Radic Biol Med*. 2010;48:446-56. (IF 5.707)
146. Baronciani L, **Peyvandi F**, Punzo M, Lancellotti S, Canciani MT, Federici AB, De Cristofaro R. Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. *J Thromb Haemost*. 2010;8:416-8. (letter IF 5.439:5 = 1.088)
147. Lotta LA, Garagiola I, Palla R, Cairo A, **Peyvandi F**. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. *Hum Mutat*. 2010;31:11-9. (review: IF 5.956)
148. **Peyvandi F**, Palla R. Fibrinogen concentrates. *Clin Adv Hematol Oncol*. 2009;7:788-90. (commentary: IF -)
149. **Peyvandi F**. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. *Thromb Res*. 2009;124 (Suppl 2):S9-11. (IF 2.406)
150. Guella I, Rimoldi V, Asselta R, Ardissino D, Francolini M, Martinelli N, Girelli D, **Peyvandi F**, Tubaro M, Merlini PA, Mannucci PM, Duga S. Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease. *Circ Cardiovasc Genet*. 2009;2:165-72. (IF 4.043)
151. Girelli D, Martinelli N, **Peyvandi F**, Olivieri O. Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging "golden dozen" loci. *Semin Thromb Hemost*. 2009;35:671-82. (review: IF 3.214)
152. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, **Peyvandi F**, Piseddu G, Mannucci P; FIBRINOGEN CONCENTRATE STUDY GROUP. Pharmacokinetics and safety of fibrinogen concentrate. *J Thromb Haemost*. 2009;7:2064-9. (IF 6.069)
153. Spena S, Asselta R, Caccia S, Rimoldi V, Giacomelli SH, Tagliaferri A, **Peyvandi F**, Castaman G, Duga S. Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency. *Thromb Haemost*. 2009;102:603-6. (letter IF 4.451:5 = 0.890)
154. Siboni SM, Spreafico M, Calò L, Maino A, Santagostino E, Federici AB, **Peyvandi F**. Gynaecological and obstetrical problems in women with different bleeding disorders. *Haemophilia*. 2009;15:1291-9. (IF 2.505)
155. Menegatti M, **Peyvandi F**. Factor X deficiency. *Semin Thromb Hemost*. 2009;35:407-15. (review: IF 3.214)
156. Spreafico M, **Peyvandi F**. Combined Factor V and Factor VIII Deficiency. *Semin Thromb Hemost*. 2009;35:390-9. (review: IF 3.214)
157. Asselta R, **Peyvandi F**. Factor V deficiency. *Semin Thromb Hemost*. 2009;35:382-9. (review: IF 3.214)
158. **Peyvandi F**, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. *Semin Thromb Hemost*. 2009;35:349-55. (review: IF 3.214)
159. **Peyvandi F**, Favaloro EJ. Rare bleeding disorders. *Semin Thromb Hemost*. 2009;35:345-7. (editorial: IF 3.214:5 = 0.643)
160. James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Konkle BA, Martínez-Perez O, McLintock C, **Peyvandi F**, Winikoff R. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. *Am J Obstet Gynecol*. 2009;201:12.e1-8. (IF 3.278)
161. Mannucci PM, **Peyvandi F**. Autoimmune hemophilia at rescue. *Haematologica*. 2009;94:459-61. (editorial: IF 6.416:5 = 1.283)
162. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, **Peyvandi F**, Batorova A, Lapecorella M, Schved JF, Ingerslev J, Mariani G; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. *J Thromb Haemost*. 2009;7:774-9 (IF 6.069)
163. Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Trégouët DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, **Peyvandi F**, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, Zeller T, Wild P, Schwarz DF, Tiret L, Perret C, Schreiber S, El Mokhtari NE, Schäfer A, März W, Renner W, Bugert P, Klüter H, Schrezenmeir J, Rubin D, Ball SG, Balmforth AJ, Wichmann HE, Meitinger T, Fischer M, Meisinger C, Baumert J, Peters A, Ouwehand WH; Italian Atherosclerosis, Thrombosis, and Vascular Biology Working Group; Myocardial

- Infarction Genetics Consortium; Wellcome Trust Case Control Consortium; Cardiogenics Consortium, Deloukas P, Thompson JR, Ziegler A, Samani NJ, Schunkert H. New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat Genet.* 2009;41:280-2. (IF 34.284)
164. Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, **Peyvandi F**, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonzin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemes J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS; Wellcome Trust Case Control Consortium, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, König I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthaï W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Hüge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, König IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Hólm H, Thorleifsson G, Thorsteinsdóttir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Altshuler D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet.* 2009;41:334-41. (IF 34.284)
165. Karimi M, Jafari H, Lahsaeizadeh S, Afrasiabi A, Akbari A, Dehbozorgian J, Ardeshiri R, Guella I, Asselta R, **Peyvandi F**. Factor XI deficiency in Southern Iran: identification of a novel missense mutation. *Ann Hematol.* 2009;88:359-63. (IF 2.919)
166. Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, Afrasiabi R, Ramzi M, De Cristofaro R, **Peyvandi F**. The first deletion mutation in the TSP1-6 repeat domain of ADAMTS-13 in a family with inherited thrombotic thrombocytopenic purpura. *Hematologica.* 2009;94:289-93. (IF 6.416)
167. **Peyvandi F**, Lotta LA, Mannucci PM. Inhibitors of factor VIII in hemophilia. *N Engl J Med.* 2009;361:309. (commentary IF 47.050:5 = 9.410)
168. **Peyvandi F**, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. *Haematologica.* 2008;93:232-9. (IF 5.978)
169. Mannucci PM, **Peyvandi F**. Thrombophilia screening: little role for the JAK2V617F mutation. *Mayo Clin Proc.* 2008;83:398-9. (commentary IF 4.811:5 = 0.962)
170. Margaglione M, Castaman G; Morfini M, Rocino A, Santagostino E, Tagariello G, Tagliaferri AR, Zanon E, Biccocchi MP, Castaldo G, **Peyvandi F**, Santacroce R, Torricelli F, Grandone E, Mannucci PM; Aice-Genetics Study Group. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. *Hematologica* 2008;93:722-8. (IF 5.978)
171. Zhang B, Spreafico M, Zheng C, Yang A, Platzer P, Callaghan MU, Avci Z, Ozbek N, Mahlangu J, Haw T, Kaufman RJ, Marchant K, Tuddenham E, Selidsohn U, **Peyvandi F**, Ginsburg D. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. *Blood* 2008;111:5592-600. (IF 10.432)
172. Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, **Peyvandi F**. Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. *Hematologica* 2008;93:934-8. (IF 5.978)
173. Di Stasio E, Lancellotti S, **Peyvandi F**, Palla R, Mannucci PM, de Cristofaro R. Mechanistic studies on ADAMTS-13 catalysis. *Biophys J* 2008;95:2450-61. (IF 4.683)
174. **Peyvandi F**, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. *Haemophilia* 2008;14:202-10. (review: IF 2.394)
175. Franchini M, **Peyvandi F**, Mannucci PM. The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. *Trends cardiovasc Med.* 2008;18:157-62. (review: IF 4.121)
176. Tuddenham EG, Ingerslev J, Sorensen LN, Christiansen K, Mariani G, **Peyvandi F**, Waddington SN,

- Buckley SM, Kochanek S, Chuah MK, Vandendriessche T, Berntorp E. Genetic aspects and research development in haemostasis. *Haemophilia* 2008;14:113-8. (review: IF 2.394)
177. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, **Peyvandi F**. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. *Pharmacogenomics*. 2008;9:1237-50. (IF 3.551)
 178. Tripodi A, **Peyvandi F**, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer Hovinga JA, Lammle B, de Meyer SF, Plaimauer B, vanhoorelbeke K, Varadi K, Mannucci PM. Second collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). *J Thromb Haemost*. 2008;6:1534-41. (IF 6.291)
 179. **Peyvandi F**, Spreafico M. National and International registries of rare bleeding disorders. *Blood Transfus*. 2008;6:s45-8. (conference paper: IF -)
 180. Dall'Osso C, Guella I, Duga S, Locatelli N, Paraboschi EM, Spreafico M, Afrasiabi A, Pechlaner C, **Peyvandi F**, Tenchini ML, Asselta R. Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. *Haematologica*. 2008;93:1505-13. (IF 5.978)
 181. Garagiola I, Valsecchi C, Lavoretano S, Oren H, Bohm M, **Peyvandi F**. Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. *Haematologica*. 2008;93:1678-85. (IF 5.978)
 182. Platè M, Asselta R, Spina S, Spreafico M, Fagoonee S, **Peyvandi F**, Tenchini ML, Duga S. Congenital hypofibrinogenemia: characterization of two missense mutations affecting fibrinogen assembly and secretion. *Blood Cells Mol Dis*. 2008;41:292-7. (IF 2.749)
 183. Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F. A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. *Haemophilia*. 2008;14:66. (letter IF 2.394:5 = 0.480)
 184. Kalina U, Stohr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, **Peyvandi F**. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. *Blood Coagul Fibrinolysis*. 2008;19:777-83. (IF 1.398)
 185. Spreafico M, **Peyvandi F**. Combined FV and FVIII deficiency. *Hemophilia*. 2008;14:1201-8. (IF 2.394)
 186. Mannucci PM, Spreafico M, **Peyvandi F**. Genetics of warfarin response. *N Engl J Med* 2008;358:2743; author reply 2743-4. (commentary IF 50.017: 5 = 10.003)
 187. Mannucci PM, Spreafico M, **Peyvandi F**. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. *J Thromb Haemost*. 2008;6:1450-2. (commentary IF 6.291: 5 = 1.258)
 188. Siboni SM, Spreafico M, Menegatti M, Martinelli I, **Peyvandi F**. Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. *Blood Coagul Fibrinolysis* 2007;18:81-4. (IF 1.373)
 189. Monaldini L, Asselta R, Duga S, **Peyvandi F**, Karimi M, Malcovati M, Tenchini ML. Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. *Thromb Haemost* 2007;97:546-51. (IF 3.501)
 190. **Peyvandi F**. Rare coagulation disorders: an emerging issue. *Blood Transfus*. 2007;5:185-6. (editorial: IF -)
 191. Plate M, Asselta R, **Peyvandi F**, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. *Biochim Biophys Acta* 2007;1772:781-7. (IF 2.371)
 192. Feys HB, Canciani MT, **Peyvandi F**, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. *Br J Haematol* 2007;138:534-40. (IF 4.490)
 193. Meroni PL, **Peyvandi F**, Foco L, Bernardinelli L, Fève R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. *Journal of Thrombosis Haemostasis* 2007;5:2421-8. (IF 5.947)
 194. Jayandharan G, Spreafico M, Viswabandya A, Chandy M, Srivastava A, **Peyvandi F**. Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India. *Haemophilia* 2007;13:413-9. (IF 1.947)
 195. Mannucci PM, Gringeri A, **Peyvandi F**, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). *Haemophilia* 2007;13 (Suppl. 5):65-8. (IF 1.947)
 196. Afrasiabi A, Lecchi A, Artoni A, Karimi M, Ashouri E, **Peyvandi F**, Mannucci PM. Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. *Platelets* 2007;18:409-13. (IF 1.915)
 197. Mannucci PM, **Peyvandi F**. TTP and ADAMTS13: When Is Testing Appropriate? *Hematology Am Soc Hematol Educ Program*. 2007:121-6. (review: IF 1.915)
 198. Zwicker JI, **Peyvandi F**, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA,

- Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. *Blood* 2006;108:1280-3. (IF 10.370)
199. Zhang B, McGee B, Yamaoka JS, Guglielmone H, Downes KA, Minoldo S, Jarchum G, **Peyvandi F**, de Bosch NB, Ruiz-Saez A, Chatelain B, Olpinski M, Bockenstedt P, Sperl W, Kaufman RJ, Nichols WC, Tuddenham EG, Ginsburg D. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. *Blood* 2006;107:1903-7. (IF 10.370)
200. Zivelin A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conard J, **Peyvandi F**, Kyrle PA, Bertina R, Peyvandi F, Emmerich J, Seligsohn U. Prothrombin G20210A is an ancestral prothrombotic mutation that occurred in caucasians approximately 24,000 years ago. *Blood* 2006;107:4666-8. (IF 10.370)
201. **Peyvandi F**, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannucci PM. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. *Hum Mut* 2006;27:330-6. (IF 6.473)
202. De Cristofaro R, **Peyvandi F**, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride binding site in von willebrand factor (VWF): Energetics and conformational effects on the VWF/ADAMTS-13 interaction. *J Biol Chem* 2006;281:30400-11. (IF 5.808)
203. De Cristofaro R, Carotti A, Akhavan S, Palla R, **Peyvandi F**, Altomare C, Mannucci PM. The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na⁺ binding. *FEBS J* 2006;273:159-69. (IF 3.033)
204. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, Saibeni S, **Peyvandi F**, Bossa F, Zagaria C, Andriulli A, Devoto M, Annese V. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. *Aliment Pharmacol Ther* 2006;23:497-506. (IF 3.287)
205. Khalife H, Muwakkit S, Al-Moussawi H, Dabbous I, Khoury R, **Peyvandi F**, Abboud MR. Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation. *Pediatr Blood Cancer* 2006;50:113-4. (IF 1.882)
206. Monaldini L, Asselta R, Duga S, **Peyvandi F**, Ghosh K, Malcovati M, Tenchini ML. Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. *Haematologica* 2006; 91:628-33. (IF 5.032)
207. **Peyvandi F**, Jayandharan G, Chandy M, Srivastava A, Nakaya SM, Johnson MJ, Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of haemophilia and other inherited bleeding disorders. *Haemophilia* 2006;12 (Suppl 3):82-9. (review: IF 3.073)
208. **Peyvandi F**, Kaufman RJ, Seligsohn U, Salomon O, Bolton-Maggs PH, Spreafico M, Menegatti M, Palla R, Siboni S, Mannucci PM. Rare bleeding disorders. *Haemophilia* 2006;12 (Suppl. 3):137-42. (review: IF 3.073)
209. **Peyvandi F**, Siboni SM, Lambertenghi Delilieri D, Lavoretano S, De Fazio N, Moroni B, Lambertenghi Delilieri G, Mannucci PM. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. *Br J Haematol* 2006;134:187-95. (IF 4.498)
210. **Peyvandi F**, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. *J Thromb Haemost.* 2006;4:1510-16. (letter IF 5.138: 5 = 1.030)
211. Karimi M, Sabzi A, **Peyvandi F**, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. *J Thromb Haemost.* 2006;4:701-2. (letter IF 5.138: 5 = 1.030)
212. Karimi M, Sabzi A, **Peyvandi F**, Mannucci PM. Clinical and laboratory patterns of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. *Intern Emerg Med.* 2006;1:3539. (IF -)
213. Akhavan S, Miteva MA, Villoutreix BO, Venisse L, **Peyvandi F**, Mannucci PM, Guillin MC, Bezeaud A. critical role for Gly25 in the B chain of human thrombin. *J Thromb Haemost* 2005;3:139-45. (IF 5.262)
214. Mannucci PM, Lavoretano S, **Peyvandi F**. The thrombotic microangiopathies. *Blood Transfus.* 2005;3:120-35. (review: IF -)
215. Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, **Peyvandi F**. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. *J Thromb Haemost.* 2005;3:280-6. (IF 5.262)
216. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, **Peyvandi F**, Wulff K, Schved JF, Auerswald G, Ingerslev J, Bernardi F; International factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. *Thromb Haemost.* 2005;93:481-7. (IF 3.056)
217. Germanos-Haddad M, de Moerloose P, Boehlen F, **Peyvandi F**, Neerman-Arbez M. Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. *Haematologica.* 2005;90:418-9. (IF 4.575)
218. De Cristofaro R, **Peyvandi F**, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E,

- Mannucci PM. Role of chloride ions in the modulation of the interaction between von Willebrand factor and ADAMTS-13. *J Biol Chem.* 2005;280:23295-302. (IF 5.854)
219. Rieger M, Mannucci PM, Hovinga JA, Herzog A, Gerstembauer G, Konetschny C, Zimmerman K, Scharrer I, **Peyvandi F**, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. *Blood.* 2005;106:1262-7. (IF 10.131)
220. Mohanty D, Ghosh K, Shetty S, Spreafico M, Garagiola I, **Peyvandi F**. Mutations in the MCFD2 gene and a novel mutation in the LMAN1 gene in Indian families with combined deficiency of factor V and VIII. *Am J Hematol.* 2005;79:262-6. (IF 1.612)
221. Spina L, Saibeni S, Battaglioli T, **Peyvandi F**, De Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. *Am J Gastroenterol.* 2005;100:2036-41. (IF 5.116)
222. **Peyvandi F**, Garagiola I, Palla R, Marziliano N, Mannucci PM. Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3' untranslated region of the factor VII (FVII) gene: Molecular characterisation of patient with severe FVII deficiency. *Hum Mut.* 2005;26:455-61. (IF 7.923)
223. Afrasiabi A, Artoni A, Karimi M, **Peyvandi F**, Ashouri E, Mannucci PM. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. *Clin Lab Haematol.* 2005;27:324-7. (IF -)
224. **Peyvandi F**. The role of ADAMTS13 in the new pathogenesis of TTP. *Hematology.* 2005;10:47-8. (IF -)
225. Lukes AS, Kadir RA, **Peyvandi F**, Kouides PA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. *Fertil Steril.* 2005;84:1338-44. (IF 3.114)
226. Kouides PA, Conard J, **Peyvandi F**, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. *Fertil Steril.* 2005;84:1345-51. (IF 3.114)
227. Frasers IS, Bonnar J, **Peyvandi F**. Requirements for research investigations to clarify the relationships and management of menstrual abnormalities in women with hemostatic disorders. *Fertil Steril.* 2005;84:1360-5. (IF 3.114)
228. **Peyvandi F**. Carrier detection and prenatal diagnosis of hemophilia in developing countries. *Semin Thromb Hemost.* 2005;31:544-54. (IF 2.077)
229. **Peyvandi F**, Bernardinelli L, Martini CH, Celli P, Mannucci PM. Factor VII gene polymorphisms are not associated with myocardial infarction in young women. *J Thromb Haemost.* 2005;4:803-4. (letter IF 5.262:5 = 1.052)
230. Tripodi A, Chantarangkul V, Menegatti M, Tagliabue L, **Peyvandi F**. Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. *Clin Chem.* 2005;51:1310-1. (letter IF 7.717:5 = 1.543)
231. Asselta R, Duga S, Spena S, **Peyvandi F**, Castaman G, Malcovati M, Mannucci PM, Tenchini ML. Missense or splicing mutation? The case of a fibrinogen B β -chain mutation causing severe hypofibrinogenemia. *Blood.* 2004;103:3051-4. (IF 9.782)
232. Menegatti M, Karimi M, Garagiola I, Mannucci P, **Peyvandi F**. A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency. *Am J Hematol.* 2004;77:90-1. (IF 1.701)
233. **Peyvandi F**, Tagliabue L, Menegatti M, Karimi M, Komaromi I, Katona E, Muszbek L, Mannucci PM. Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. *Hum Mutat.* 2004;23:98-108. (IF 6.845)
234. De Cristofaro R, Akhavan S, Altomare C, Carotti A, **Peyvandi F**, Mannucci PM. A natural prothrombin mutant reveals an unexpected influence of the A-chain's structure on the activity of human α -thrombin. *J Biol Chem.* 2004;279:13035-43. (IF 6.355)
235. **Peyvandi F**, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. *Clin Pharmacol Ther.* 2004;75:198-203. (IF 6.825)
236. Mannucci PM, Duga S, **Peyvandi F**. Recessively inherited coagulation disorders. *Blood* 2004;104:1243-52. (IF 9.782)
237. Karimi M, **Peyvandi F**, Siboni S, Ardeshiri R, Gringeri A, Mannucci PM. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. *Haemophilia.* 2004;10:367-9. (IF 2.078)
238. D'Andrea G, Bossone A, Lupone MR, **Peyvandi F**, Maisto G, Perricone F, Grandone E, Margaglione M. Molecular characterization of a factor VII deficient patient supports the importance of the second epidermal growth factor-like domain. *Haematologica.* 2004;89:979-84. (IF 4.192)
239. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, **Peyvandi F**. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. *Am J Hematol.* 2004;77:198-9. (IF 1.701)
240. Spena S, Duga S, Asselta R, **Peyvandi F**, Mahasandana C, Malcovati M, Tenchini ML. Congenital afibrinogenemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen A α -chain gene. *Eur J Hum Genet.* 2004;12:891-8. (IF 2.741)

241. **Peyvandi F**, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. *Br J Haematol.* 2004;127:433-9. (IF 3.195)
242. Zadra G, Asselta R, Malcovati M, Santagostino E, **Peyvandi F**, Mannucci PM, Tenchini ML, Duga S. Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. *Haematologica.* 2004;89:1332-40. (IF 4.192)
243. **Peyvandi F**, De Cristofaro R, Garagiola I, Palla R, Akhavan S, Landolfi R, Mannucci PM. The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. *Br J Haematol.* 2004;127:576-84. (IF 3.195)
244. Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and development of acute myocardial infarction at a young age. *Circulation.* 2003;107:1117-22. (IF 11.164)
245. Duga S, Montefusco MC, Asselta R, Malcovati M, **Peyvandi F**, Santagostino E, Mannucci PM, Tenchini ML. Arg2074Cys missense mutation in the C2-domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. *Blood.* 2003;101:173-7. (IF 10.120)
246. Mannucci PM, Karimi M, Mosalaei A, Canciani MT, **Peyvandi F**. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). *Haematologica.* 2003;88:454-8. (IF 3.453)
247. Baronciani L, Cozzi G, Canciani MT, **Peyvandi F**, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. *Blood Cells Mol Dis.* 2003;30:264-70. (IF 1.991)
248. Montefusco MC, Duga S, Asselta R, Malcovati M, **Peyvandi F**, Santagostino E, Mannucci PM, Tenchini ML. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. *Blood.* 2003;102:3210-6. (IF 10.120)
249. Asselta R, Montefusco MC, Duga S, Malcovati M, **Peyvandi F**, Mannucci PM, Tenchini ML. Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain. *J Thromb Haemost.* 2003;1:1237-44. (IF -)
250. Garagiola I, Palla R and **Peyvandi F**. Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency-misdiagnosis by direct sequence analysis using a PCR product. *Prenat Diagn.* 2003;23:731-4. (IF 1.475)
251. Spena S, Asselta R, Duga S, Malcovati M, **Peyvandi F**, Mannucci PM, Tenchini ML. Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bbeta-chain gene. *Biochim Biophys Acta.* 2003;1639:87-94. (IF 2.557)
252. Mannucci PM, **Peyvandi F**, Ardissino D. Risk of myocardial infarction and polymorphisms in candidate genes. *N Engl J Med.* 2003;348:1176-7. (commentary IF 34.833:5 = 6.970)
253. Mannucci PM, Ardissino D, Merlini PA, **Peyvandi F**. Vagaries of genetic association studies in myocardial infarction. *Blood.* 2003;102:1558-9. (commentary IF 10.120:5 = 2.024)
254. Lak M, **Peyvandi F**, Ali Sharifian A, K. Karimi, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. *J Thromb Haemost.* 2003;1:1852-3. (letter: IF -)
255. Spreafico M, **Peyvandi F**, Pizzotti D, Moia M, Mannucci PM. Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. *J Thromb Haemost.* 2003;1:2252-3. (letter: IF -)
256. **Peyvandi F**, Menegatti M, Santagostino E, Akhavan S, Uprichard J, Perry DJ, Perkins SJ, Mannucci PM. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. *British Journal of Haematology.* 2002;117:685-92. (IF 3.052)
257. Tripodi A, **Peyvandi F**, Chantarangkul V, Menegatti M, Mannucci PM. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-A cause for concern. *Thromb Haemost.* 2002;88:690-1. (letter IF 4.357:5 = 0.871)
258. **Peyvandi F**, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. *Haematologica.* 2002;87:512-4. (IF 3.226)
259. **Peyvandi F**, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. *Haemophilia.* 2002;8:308-21. (review: IF 1.113)
260. **Peyvandi F**, De Cristofaro R, Akhavan S, Carew JA, Landolfi R, Bauer KA, Mannucci PM. Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. *Thromb Haemost.* 2002;88:750-5. (IF 4.357)
261. Spena S, Duga S, Asselta R, Malcovati M, **Peyvandi F**, Tenchini ML. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen B β -chain gene causing activation of cryptic splice sites.

- Blood. 2002;100:4478-84. (IF 9.631)
262. Al Dieri RA, **Peyvandi F**, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker CH. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. *Thromb Haemost.* 2002;88:576-82. (IF 4.357)
 263. Mannucci PM, Gringeri A, **Peyvandi F**, Di Paolantonio T, Mariani M. Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. *Thromb Haemost.* 2002;87:342-3. (letter IF 4.357:5 = 0.871)
 264. Asselta R, Spena S, Duga S, **Peyvandi F**, Malcovati M, Mannucci PM, Tenchini ML. Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen B β -chain gene causing afibrinogenemia. *Haematologica.* 2002;87:855-9. (IF 3.226)
 265. **Peyvandi F**, Spreafico M, Karimi M, Zeinali S, Mannucci PM. Allele Frequency of CYP2C9 Gene Polymorphisms in Iran. *Thromb Haemost.* 2002;88:874-5. (letter IF 4.357:5 = 0.871)
 266. Akhavan S, De Cristofaro R, **Peyvandi F**, Lavoretano S, Landolfi R, Mannucci PM. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. *Blood.* 2002;100:1347-53. (IF 9.631)
 267. **Peyvandi F**, Carew JA, Perry DJ, Hanault M, Khanduri U, Perkins SJ, Mannucci PM, Bauer KA. Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15 base pair insertion in the factor VII gene. *Blood.* 2001;97:960-5. (IF 9.273)
 268. Asselta R, Duga S, Spena S, Santagostino E, **Peyvandi F**, Piseddu G, Targhetta R, Malcovati M, Mannucci PM, Tenchini ML. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs. *Blood.* 2001;98:3685-92. (IF 9.273)
 269. **Peyvandi F**, Asselta R, Mannucci PM. Autosomal recessive deficiency of coagulation factors. *Rev Clin Exp Hematol.* 2001;5:369-89. (review: IF -)
 270. **Peyvandi F**, Mannucci PM, Bucciarelli P, Zeinali S, Akhavan S, Sacchi E, Merlini PA, Perry DJ. A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. *Br J Haematol.* 2000;108:247-53. (IF 3.068)
 271. **Peyvandi F**, Jenkins VP, Mannucci PM, Billio A, Zeinali S, Perkins SJ, Perry DJ. Molecular characterization and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. *Thromb Haemost.* 2000;84:250-7. (IF 4.372)
 272. **Peyvandi F**, Mannucci PM, Jenkins PV, Lee A, Coppola R, Perry DJ. Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. *Thromb Haemost.* 2000;84:635-7. (IF 4.372)
 273. Tagliabue L, Duca F, **Peyvandi F**. Apparently dominant transmission of a recessive disease: deficiency of factor VII in Iranian Jews. *Ann Ital Med Int.* 2000;15:263-6. (IF -)
 274. Lak M, **Peyvandi F**, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. *Br J Haematol.* 2000;111:1236-9. (IF 3.068)
 275. Baronciani L, Cozzi G, Canciani MT, **Peyvandi F**, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. *Thromb Haemost.* 2000;84:536-40. (IF 4.372)
 276. Hunault M, Arbini A, Carew JC, **Peyvandi F**, Bauer KA. Characterization of two naturally occurring mutations in the second Epidermal Growth Factor-like domain of factor VII. *Blood* 1999;93:1237-44. (IF 8.782)
 277. Neerman-Arbez M, Johnson KM, Morris MA, McVey JH, **Peyvandi F**, Nichols WC, Ginsburg D, Rossier C, Antonarakis SE, Tuddenham EGD. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. *Blood.* 1999;93:2253-60. (IF 8.782)
 278. **Peyvandi F**, Mannucci PM. Rare coagulation disorders. *Thromb Haemost.* 1999;82:1207-14. (review IF 4.983)
 279. Lak M, Keihani M, Elahi F, **Peyvandi F**, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenemia. *Br J Haematol.* 1999;107:204-6. (IF 3.204)
 280. **Peyvandi F**, Tuddenham EGD, Akhtari M, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. *Br J Hematol.* 1998;100:773-6. (IF 3.209)
 281. **Peyvandi F**, Mannucci PM, Lak M, Abdoullahi M, Zeinali S, Sharifian R, Perry D. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. *Br J Hematol.* 1998;102:626-8. (IF 3.209)
 282. Lak M, Sharifian R, **Peyvandi F**, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. *Br J Hematol.* 1998;103:1067-69. (IF 3.209)
 283. Mannucci PM, Mari D, Merati G, **Peyvandi F**, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S,

- Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. *Arterioscler Thromb Vasc Biol.* 1997;17:755-9. (IF 5.317)
284. Faioni EM, Merati G, **Peyvandi F**, Bettini P, Mannucci PM. The G1456 to T mutation in the thrombomodulin gene is not frequent in patients with venous thrombosis. *Blood.* 1997;89:1467. (letter IF 9.507:5 = 1.901)
285. **Peyvandi F**, Mannucci PM, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. *Hemophilia.* 1997;3:242-6. (IF 0.971)
286. Ardissino D, **Peyvandi F**, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506→Gln) mutation in young survivors of myocardial infarction. *Thromb Haemost.* 1996;75:701-2. (IF 4.267)
287. Mannucci PM, Duca F, **Peyvandi F**, Tagliabue L, Merati G, Martinelli I, Cattaneo M. Frequency of factor V Arg506Gln in Italians. *Thromb Haemost.* 1996;75:694. (letter IF 4.267:5 = 0.855)
288. **Peyvandi F**, Faioni EM, Moroni GA, Rosti A, Leo L, Moia M. Autoimmune protein S deficiency and deep vein thrombosis after chickenpox. *Thromb Haemost.* 1996;75:212-3. (IF 4.267)

Chapters in book

1. **F. Peyvandi**, M. Menegatti and SM. Siboni. Rare Coagulation Factor Defects in Pregnancy in Disorders of Thrombosis and Hemostasis in Pregnancy edited by H. Cohen and P. O'Brien. 2nd edition 2015. ISBN 978-3-319-15119-9
2. Federici AB, Mannucci PM, **Peyvandi F**. (2015). Malattie emorragiche congenite e acquisite. p. 285-338. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERI G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. *Manuale di Ematologia II Edizione.* TORINO: Minerva Medica S.p.a, ISBN: 978-88-7711-816-5
3. **Peyvandi F**, Ferrari B, Cannavo' A, Rossio R. (2015). Microangiopatie trombotiche. p. 339-348. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERI G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. *Manuale di Ematologia II Edizione.* TORINO: Minerva Medica S.p.a, ISBN: 978-88-7711-816-5
4. **Flora Peyvandi** and Marzia Menegatti (2014). Factor V and combined Factor V and VIII deficiencies. p. 403-412. In *TEXTBOOK OF HEMOPHILIA*, 3rd edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Blackwell Publishing Ltd. ISBN 978-1-118-39824-1
5. **Flora Peyvandi**, Marzia Menegatti and Simona Maria Siboni (2012). Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. p 131. in *DISORDERS OF THROMBOSIS AND HEMOSTASIS IN PREGNANCY* edited by H. COHEN AND P. O'BRIEN. ISBN 978-1-4471-4410-6, ISBN 978-1-4471-4411-3
6. Pier M Mannucci, **Flora Peyvandi** and Roberta Palla (2010). Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). p. 860-871. In *POSTGRADUATE HAEMATOLOGY* 6th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM, A.R. GREEN. Wiley-Blackwell. ISBN 9781405191807
7. **Flora Peyvandi** and Marzia Menegatti (2010). Rare bleeding disorders. P. 813-838. In *POSTGRADUATE HAEMATOLOGY* 6th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM, A.R. GREEN. Wiley-Blackwell. ISBN 9781405191807
8. **Flora Peyvandi** and Marta Spreafico (2010). Factor V and combined Factor V and VIII deficiencies. P. 332-340. In *TEXTBOOK OF HEMOPHILIA*, 2nd edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Wiley-Blackwell. ISBN 9781405169141
9. **Flora Peyvandi** (2009). Rare Bleeding Disorders. p. 54-64. In *INHERITED BLEEDING DISORDERS IN WOMEN*, 1st edition, by CHRISTINE A. LEE, REZAN A. KADIR AND PETER A. KOUIDES. Wiley-Blackwell. ISBN 978-1-4051-6915-8
10. Federici AB, Mannucci PM, **Peyvandi F**. (2008). Patologie della coagulazione. p. 229-279. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERI G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. *Manuale di Ematologia.* TORINO: Minerva Medica S.p.a, ISBN/ISSN: 10: 88-7711-618-8
11. **Peyvandi F**, Lavoretano S, Palla R. (2008). Microangiopatie trombotiche. p. 281-288. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERI G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. *Manuale di Ematologia.* TORINO: Minerva Medica S.p.a, ISBN/ISSN: 10: 88-7711-618-8
12. Pier M Mannucci and **Flora Peyvandi** (2005). Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). p. 876-884. In *POSTGRADUATE HAEMATOLOGY* 5th

edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM. Blackwell Publishing Ltd. ISBN 9781405191807

13. **Flora Peyvandi** and Pier M Mannucci (2005). Congenital bleeding: autosomal recessive disorders. p. 842-858. In POSTGRADUATE HAEMATOLOGY 5th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM. Blackwell Publishing Ltd. ISBN 9781405191807
14. **Flora Peyvandi** and Marta Spreafico (2005). Factor V and combined Factor V and VIII deficiencies. p. 306. In TEXTBOOK OF HEMOPHILIA, 1st edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Blackwell Publishing Ltd. ISBN 1405127694
15. Stefano Duga, Rosanna Asselta, Elena Santagostino, **Flora Peyvandi**, Maria Luisa Tenchini, Pier Mannuccio Mannucci (2004). Coagulopatie ereditarie. p. 381-410. In MALATTIE GENETICHE – MOLECOLE E GENI – DIAGNOSI, PREVENZIONE E TERAPIA edited by CAO A, DALLAPICCOLA B AND NOTARANGELO LD. Piccin Nuova Libreria. ISBN: 978-88-299-1652-8
16. David Perry and **Flora Peyvandi** (1999). Detection of DNA by silver staining. p. 63-9. In HEMOSTASIS AND THROMBOSIS PROTOCOLS: METHODS IN MOLECULAR MEDICINE. Edited by DAVID J. PERRY AND JOHN K. PASI. Humana Press. ISBN 978-0896034198

Non peer-reviewed publications

1. Patients Informative Booklet on the Establishment of a European Network of Rare Bleeding Disorders (EN-RBD) project funded by EC (downloadable at www.rbdd.eu) (2011), by **F. Peyvandi**, R. Palla, M. Menegatti, S. Malosio.
2. **F. Peyvandi**, A. Cairo, R. Palla, M. Menegatti. Registri nazionali ed internazionali sulle malattie rare della coagulazione. Focus Emostasi Anno 4 - N. 1 - Febbraio 2011. Four-monthly magazine edited by Alter M&P S.r.l., Milan, Italy.
3. **Peyvandi F**, Palla R, Menegatti M. (2008). Rare coagulation defects. Yearbook 2008 - Highlights of XXVIII International Congress of Haemophilia. p. 40-45 AICEcongressi.
4. Patients Informative Booklet on the Women with rare bleeding disorders project (2007), by **F. Peyvandi**, M. Spreafico, R. Palla, S. Lavoretano, I. Garagiola, S.M. Siboni.
5. Patients Informative Booklet. Dalla diagnosi di portatrice di Emofilia alla diagnosi prenatale (downloadable at www.aiceonline.it/documenti/genetica/diagnosiportatrice.pdf), by **F. Peyvandi**, L. Tagliabue, M. Menegatti, I. Garagiola, E. Santagostino. Edited by Associazione Italiana Centri Emofilia (AICE)